US20180296454A1 - Compositions for treating periodontitis and dental calculus accumulation - Google Patents
Compositions for treating periodontitis and dental calculus accumulation Download PDFInfo
- Publication number
- US20180296454A1 US20180296454A1 US16/014,834 US201816014834A US2018296454A1 US 20180296454 A1 US20180296454 A1 US 20180296454A1 US 201816014834 A US201816014834 A US 201816014834A US 2018296454 A1 US2018296454 A1 US 2018296454A1
- Authority
- US
- United States
- Prior art keywords
- urea
- incubation
- serine
- subject
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 116
- 208000006558 Dental Calculus Diseases 0.000 title claims abstract description 14
- 206010044029 Tooth deposit Diseases 0.000 title claims abstract description 14
- 238000009825 accumulation Methods 0.000 title claims description 9
- 201000001245 periodontitis Diseases 0.000 title claims description 8
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 67
- 238000000034 method Methods 0.000 claims abstract description 42
- 208000028169 periodontal disease Diseases 0.000 claims abstract description 25
- FENRSEGZMITUEF-ATTCVCFYSA-E [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OP(=O)([O-])O[C@@H]1[C@@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H]1OP(=O)([O-])[O-] Chemical group [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OP(=O)([O-])O[C@@H]1[C@@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H]1OP(=O)([O-])[O-] FENRSEGZMITUEF-ATTCVCFYSA-E 0.000 claims description 31
- 229940083982 sodium phytate Drugs 0.000 claims description 31
- 241000282414 Homo sapiens Species 0.000 claims description 29
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims description 19
- 235000002949 phytic acid Nutrition 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 15
- 229910052791 calcium Inorganic materials 0.000 claims description 15
- 239000011575 calcium Substances 0.000 claims description 15
- -1 gums Substances 0.000 claims description 14
- 210000003298 dental enamel Anatomy 0.000 claims description 13
- 239000002552 dosage form Substances 0.000 claims description 10
- 208000007565 gingivitis Diseases 0.000 claims description 10
- 210000003296 saliva Anatomy 0.000 claims description 9
- CDAISMWEOUEBRE-UHFFFAOYSA-N inositol Chemical group OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 150000004712 monophosphates Chemical class 0.000 claims description 6
- 210000004268 dentin Anatomy 0.000 claims description 5
- 229920002261 Corn starch Polymers 0.000 claims description 4
- 239000008120 corn starch Substances 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 3
- 239000007900 aqueous suspension Substances 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 229960000367 inositol Drugs 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000003086 colorant Substances 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 242
- 239000004202 carbamide Substances 0.000 description 121
- 238000011534 incubation Methods 0.000 description 113
- 239000013049 sediment Substances 0.000 description 87
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 66
- 238000011282 treatment Methods 0.000 description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 31
- 150000001875 compounds Chemical class 0.000 description 30
- 201000010099 disease Diseases 0.000 description 28
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 22
- 230000004044 response Effects 0.000 description 22
- 210000000214 mouth Anatomy 0.000 description 19
- 239000008194 pharmaceutical composition Substances 0.000 description 18
- 235000002639 sodium chloride Nutrition 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000006228 supernatant Substances 0.000 description 13
- 239000004471 Glycine Substances 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 10
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 10
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 10
- 235000004279 alanine Nutrition 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 10
- 230000002265 prevention Effects 0.000 description 10
- 239000004474 valine Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000004475 Arginine Substances 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 9
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 9
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 9
- 239000004473 Threonine Substances 0.000 description 9
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 9
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 9
- 235000018417 cysteine Nutrition 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 208000002064 Dental Plaque Diseases 0.000 description 8
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 8
- 229960003067 cystine Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- 239000004472 Lysine Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 7
- 235000004554 glutamine Nutrition 0.000 description 7
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 7
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 6
- 235000009582 asparagine Nutrition 0.000 description 6
- 229960001230 asparagine Drugs 0.000 description 6
- 235000003704 aspartic acid Nutrition 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 6
- 229960000310 isoleucine Drugs 0.000 description 6
- 235000014705 isoleucine Nutrition 0.000 description 6
- 235000005772 leucine Nutrition 0.000 description 6
- 229930182817 methionine Natural products 0.000 description 6
- 230000000813 microbial effect Effects 0.000 description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000013922 glutamic acid Nutrition 0.000 description 5
- 239000004220 glutamic acid Substances 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- 241000628997 Flos Species 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000013877 carbamide Nutrition 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000003731 gingival crevicular fluid Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002324 mouth wash Substances 0.000 description 3
- 230000003239 periodontal effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000001479 atomic absorption spectroscopy Methods 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 239000000551 dentifrice Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229940068041 phytic acid Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000005956 quaternization reaction Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000000606 toothpaste Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000003604 ureolytic effect Effects 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000034048 Asymptomatic disease Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000252095 Congridae Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CTPQAXVNYGZUAJ-UHFFFAOYSA-N Inositol pentaphosphate Natural products OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O CTPQAXVNYGZUAJ-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 208000005888 Periodontal Pocket Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002272 anti-calculus Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008953 bacterial degradation Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 210000004513 dentition Anatomy 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000000668 effect on calcium Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 150000004001 inositols Chemical class 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000036346 tooth eruption Effects 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/732—Starch; Amylose; Amylopectin; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B64—AIRCRAFT; AVIATION; COSMONAUTICS
- B64G—COSMONAUTICS; VEHICLES OR EQUIPMENT THEREFOR
- B64G1/00—Cosmonautic vehicles
- B64G1/22—Parts of, or equipment specially adapted for fitting in or to, cosmonautic vehicles
- B64G1/40—Arrangements or adaptations of propulsion systems
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B64—AIRCRAFT; AVIATION; COSMONAUTICS
- B64G—COSMONAUTICS; VEHICLES OR EQUIPMENT THEREFOR
- B64G1/00—Cosmonautic vehicles
- B64G1/22—Parts of, or equipment specially adapted for fitting in or to, cosmonautic vehicles
- B64G1/40—Arrangements or adaptations of propulsion systems
- B64G1/407—Solar sailing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B64—AIRCRAFT; AVIATION; COSMONAUTICS
- B64G—COSMONAUTICS; VEHICLES OR EQUIPMENT THEREFOR
- B64G1/00—Cosmonautic vehicles
- B64G1/22—Parts of, or equipment specially adapted for fitting in or to, cosmonautic vehicles
- B64G1/46—Arrangements or adaptations of devices for control of environment or living conditions
- B64G1/50—Arrangements or adaptations of devices for control of environment or living conditions for temperature control
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B64—AIRCRAFT; AVIATION; COSMONAUTICS
- B64G—COSMONAUTICS; VEHICLES OR EQUIPMENT THEREFOR
- B64G1/00—Cosmonautic vehicles
- B64G1/22—Parts of, or equipment specially adapted for fitting in or to, cosmonautic vehicles
- B64G1/64—Systems for coupling or separating cosmonautic vehicles or parts thereof, e.g. docking arrangements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/87—Application Devices; Containers; Packaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Definitions
- compositions comprising serine and an organic mono- or multi-phosphate salt (e.g., a phytate) for the treatment and/or prevention of periodontitis (e.g., gingivitis) and/or dental calculus formation or development.
- an organic mono- or multi-phosphate salt e.g., a phytate
- the human oral cavity contains one of the most densely populated and complex mixed microbial floras that inhabit the human body (Takhashi, N., 2005).
- One major component of the oral mixed microbial flora is comprised of fermentable carbohydrate metabolizing types of microorganisms that are found particularly in supra-gingival dental sites, namely tooth pits, fissures, and interproximal tooth embrasures.
- Fermentable dietary carbohydrates and corresponding fermentative oral bacteria are easily and regularly retained in many of these intra-oral locations, sheltered from saliva and readily able to interact to produce abundant acidity and an acidic pH.
- Such acidity is principally due to the generation of lactic acid, an entity that can readily solubilize tooth calcium phosphate, the dominant mineral element comprising the mineralized tissues (i.e., enamel, dentin, and cementum) of human teeth.
- alkaline In contrast to acidity, if the environment of the teeth gingivae is alkaline (e.g., because of elevated urea levels that occur in many individuals' gingival crevicular fluid), alkaline conditions may be expected to prevail around the necks of the teeth to where, instead of dental caries, dental calculus and/or periodontitis indices are more evident.
- the dental calculus/periodontitis entity involves a mixed microbial flora that mainly populates the regions around the necks of the teeth and extends into adjacent gingival and subgingival dentition sites.
- the bacteria involved in these locations are mainly non-fermenting. They have been proven to be largely comprised of proteolytic, putrefactive microorganisms that readily metabolize nitrogenous substrates, particularly such derived from the gingivae and adjacent gingival crevicular and periodontal pocket fluids and tissues (Takhashi, N., 2005). Of particular note is that this includes involvement with urea and amino acids, the main end-products of the numerous, common human body amino acids that circulate in the blood vessels throughout the human body.
- gingival and periodontal crevices containing urea are conducive to bacterial degradation to ammonia and can exhibit a high alkaline pH.
- a high pH is an essential element responsible for the easy formation of calcium phosphate deposits (generally referred to as dental plaque or calculus), which readily form around the base of the crowns of teeth (Denepitiya L. and Kleinberg I., 1982 ; Arch. Oral Biol.; Salako, N. O. and Kleinberg, I., 1989; Jin, Y. and Yip, H.-K., 2002).
- these crevices promote the proliferation of additional ureolytic and proteolytic bacteria, which in turn promote the formation of additional calculus.
- gingivitis gingivitis
- Periodontal disease e.g., gingivitis
- Talacobson, M. and Kesel, R. G., 1950 Central to these processes are the formation and flow of gingival/periodontal crevicular fluid (Golub, L. M., Borden, S. M., and Kleinberg, I., 1971), which characterizes and helps perpetuate these periodontal disease conditions by maintaining a high pH in the environment.
- amino acids can serve as important bacterial substrates and can thereby help facilitate both the accumulation of dental plaque and the development of periodontal disease (including gingivitis, with symptoms including bleeding gums and putrefactive gingivae).
- periodontal disease including gingivitis, with symptoms including bleeding gums and putrefactive gingivae.
- urea has been demonstrated to promote tooth and gingival alkalinity, enhancing the accumulation of plaque-causing bacteria on teeth and other surfaces in the oral cavity (Kleinberg, I., 1967, Arch. Oral Biol., 1475-1484).
- Numerous other amino acids can serve as nitrogenous substrates that contribute to varying degrees of alkalinity and promote periodontal disease, albeit to a lesser degree than urea (Biswas, S. D. and Kleinberg, I., 1971; Golub, L. M., Borden, S. M., and Kleinberg, I., 1971; Kleinberg, I. and Hall, G., 1968).
- amino acids function to maintain a balance of alkalin
- compositions comprising serine and an organic mono- or multi-phosphate salt (e.g., a phytate) which can treat and/or prevent periodontal disease (e.g., gingivitis, e.g., by reducing gingival alkalinity), and/or treat and/or prevent dental calculus accumulation, formation, and/or development.
- periodontal disease e.g., gingivitis, e.g., by reducing gingival alkalinity
- dental calculus accumulation, formation, and/or development e.g., dental calculus, formation, and/or development.
- the present disclosure provides an oral composition including serine and one or more organic mono-phosphate or multi-phosphate salts, wherein the pH of the composition is between about 6.0 and about 9.5.
- the pH of the composition can be, e.g., between about 6.1 and about 6.3.
- the pH of the composition can be, e.g., between about 6.7 and about 7.0.
- the organic mono-phosphate or multi-phosphate salts can include, e.g., one or more biological salts.
- the biological salts can include, e.g., one or more inositol (e.g., phytate) salts.
- the phytates can include, e.g., sodium phytate.
- the composition can include, e.g., serine phytate.
- the orally acceptable dosage form can be, e.g., a chewable tablet, a piece of chewing gum, a dentifrice, a mouthwash, a rinse, and/or a toothpaste.
- any of the above oral compositions can include one or more devices.
- One or more surfaces of the device can include, e.g., serine and one or more organic mono-phosphate or multi-phosphate salts, wherein the pH of the surface is between about 6.0 and about 9.5.
- the pH of the surface can be, e.g., between about 6.1 and about 6.3.
- the pH of the surface can be, e.g., between about 6.7 and about 7.0.
- the organic mono-phosphate or multi-phosphate salts can include, e.g., one or more biological salts.
- the biological salts can include, e.g., one or more inositols (e.g., phytates).
- the phytates can include, e.g., sodium phytate.
- the composition can include, e.g., serine phytate.
- the device can be, e.g., a brush, a piece of floss, a flosser, an irrigator, a mouth guard, a pick, a retainer, a scraper, a spatula, and/or a stick.
- the document also provides a method of treating or preventing plaque or periodontal disease (e.g., gingivitis), the method comprising administering an effective amount of any of the above oral compositions to a subject (e.g., a human) having, or at risk of having, plaque or periodontal disease.
- a subject e.g., a human
- the oral composition can be, e.g., applied to one or more teeth (e.g., the exposed enamel, dentine, and/or cementum of one or more teeth) of the subject.
- Periodontal disease and “periodontitis” are used interchangeably herein, and refer to one or more periodontal (gum) diseases in an oral cavity (e.g., gingivitis).
- plaque and “calculus” are used interchangeably herein, and refer to dental plaque or calculus on one or more hard (e.g., teeth) or soft (e.g., mucosal tissue) surfaces in an oral cavity.
- hard e.g., teeth
- soft e.g., mucosal tissue
- the term “overnight” is defined as being about 21 hours.
- the terms “about” and “approximately” are defined as being within plus or minus 10% of a given value or state, preferably within plus or minus 5% of said value or state.
- FIG. 1 is a graph showing the pH response of salivary sediment with or without serine, urea, or a mixture of serine and urea.
- FIG. 2 is a graph showing the pH response of salivary sediment with or without glycine, urea, or a mixture of glycine and urea.
- FIG. 3 is a graph showing the pH response of salivary sediment with or without alanine, urea, or a mixture of alanine and urea.
- FIG. 4 is a graph showing the pH response of salivary sediment with or without valine, urea, or a mixture of valine and urea.
- FIG. 5 is a graph showing the pH response of salivary sediment with or without histidine, urea, or a mixture of histidine and urea.
- FIG. 6 is a graph showing the pH response of salivary sediment with or without leucine, isoleucine, urea, or a mixture of leucine and urea or isoleucine and urea.
- FIG. 7 is a graph showing the pH response of salivary sediment with or without aspartic acid, glutamic acid, urea, or a mixture of aspartic acid and urea or glutamic acid and urea.
- FIG. 8 is a graph showing the pH response of salivary sediment with or without cystine, cysteine, urea, or a mixture of cystine and urea or cysteine and urea.
- FIG. 9 is a graph showing the pH response of salivary sediment with or without lysine, arginine, urea, or a mixture of lysine and urea or arginine and urea.
- FIG. 10 is a graph showing the pH response of salivary sediment with or without phenylalanine, tyrosine, urea, or a mixture of phenylalanine and urea or tyrosine and urea.
- FIG. 11 is a graph showing the pH response of salivary sediment with or without threonine, proline, urea, or a mixture of threonine and urea or proline and urea.
- FIG. 12 is a graph showing the pH response of salivary sediment with or without methionine, tryptophan, urea, or a mixture of methionine and urea or tryptophan and urea.
- FIG. 13 is a graph showing the pH response of salivary sediment with or without glutamine, asparagine, urea, or a mixture of glutamine and urea or asparagine and urea.
- FIG. 14 is a graph showing the pH response of salivary sediment with 6.7 or 8.3 mM serine, with or without urea.
- FIG. 15 is a graph showing the pH response of salivary sediment with 20 or 25 mM serine, with or without urea and 3 mM sodium phytate.
- FIG. 16 is a graph showing the pH response of salivary sediment with 20 or 25 mM serine, with or without urea and 6 mM sodium phytate.
- FIG. 17 is a graph showing the pH response of salivary sediment with 238 mM serine, with or without urea and 6 mM sodium phytate.
- FIG. 18 is a graph showing the pH response of salivary sediment with 238 mM serine and 6 mM sodium phytate, with or without urea and a piece of human tooth.
- FIG. 19 is a graph showing calcium release in an incubation mixture containing salivary sediment, serine, sodium phytate, and urea, with or without enamel from a human tooth.
- FIG. 20 is a graph showing the pH response of salivary sediment with 238 mM serine and 6 mM sodium phytate, with or without urea and a piece of human tooth cementum.
- FIG. 21 is a graph showing calcium release in an incubation mixture containing salivary sediment, serine, sodium phytate, and urea, with or without cementum from a human tooth.
- FIG. 22 is a graph showing the pH response of salivary sediment with 238 mM serine and 6 mM sodium phytate, with or without urea, when the initial pH was not adjusted to neutrality.
- FIG. 23 is a series of photographs showing a piece of a molar tooth.
- FIG. 24 is a photograph showing the roots of a molar tooth.
- compositions comprising serine and an organic mono- or multi-phosphate salt (e.g., a biological salt such as a phytate) are useful in the treatment and/or prevention of periodontal disease (e.g., gingivitis, e.g., by reducing gingival alkalinity).
- periodontal disease e.g., gingivitis, e.g., by reducing gingival alkalinity.
- the compositions disclosed herein are alternately or additionally useful in the treatment and/or prevention of plaque (e.g., by inhibiting, reducing, and/or reversing the accumulation, formation, and/or development of dental calculus).
- compositions comprising serine uniquely possess the ability, in the presence of salivary urea, to lower the pH from an alkaline level (i.e., >7.0) to about neutrality (i.e., about 7.0) or even (depending on arginine concentration) to a slightly acidic level (i.e., ⁇ 7.0).
- alkaline level i.e., >7.0
- neutrality i.e., about 7.0
- ⁇ 7.0 slightly acidic level
- a serine-containing composition to saliva provides serine as a “pH-fall” factor, as it causes a reduction in pH when converted from serine to cysteine to pyruvate to lactate by bacteria in the oral cavity.
- altering the pH of the oral cavity using such a composition can help promote the dominance of saccharidic microorganisms in subgingival dental plaque over asaccharidic microorganisms, thus reducing the overall accumulation and formation of dental calculus.
- Such serine-containing compositions are also useful in treating and preventing periodontal disease.
- organic mono- or multi-phosphate salts e.g., a biological salt such as an inositol salt (e.g., an inositol monophosphate salt, an inositol pentaphosphate salt, or an inositol hexaphosphate (a.k.a., phytate) salt such as sodium phytate and potassium phytate).
- a biological salt such as an inositol salt (e.g., an inositol monophosphate salt, an inositol pentaphosphate salt, or an inositol hexaphosphate (a.k.a., phytate) salt such as sodium phytate and potassium phytate).
- Phytates are phosphate anions with phosphate groups that readily form complexes with calcium ions, complexes easily solubilized in aqueous solutions (e.g., saliva).
- the phosphate anions present on phytates and other organic mono- or multi-phosphate salts can serve as carriers in binding to and solubilizing free calcium ions (thereby effectively removing them from saliva) and thus inhibiting the overall accumulation and formation of dental plaque.
- salivary sediment containing 28 mM urea showed a significant rise in pH from neutrality to about 9.0 after 4 hours of incubation at 37° C. ( FIG. 1 ). The pH remained about the same (dropping slightly to 8.8) after 21 hours of incubation at 37° C.
- salivary sediment containing 90 or 120 mM serine in addition to 28 mM urea showed a significantly smaller increase in pH, from neutrality to 8.22 (90 mM serine) or 8.30 (120 mM serine) after 4 hours of incubation at 37° C. After 21 hours of incubation at 37° C., the pH dropped significantly, to 7.85.
- Salivary sediment containing 90 or 120 mM glycine in addition to 28 mM urea showed a rise in pH from neutrality to 8.72 (90 mM glycine) or 8.90 (120 mM glycine) after 4 hours of incubation, falling to 8.65 (90 mM glycine) or 8.55 (120 mM glycine) after 21 hours of incubation.
- the pH fell from 6.80 to ⁇ 6.40 after 4 hours of incubation, then rose to ⁇ 7.0-7.15 after 21 hours of incubation ( FIG. 2 ).
- Salivary sediment containing 90 or 120 mM alanine in addition to 28 mM urea showed a rise in pH from neutrality to 8.82 (90 mM alanine) or 8.72 (120 mM alanine) after 4 hours of incubation, falling slightly to 8.80 (90 mM alanine) or 8.67 (120 mM alanine) after 21 hours of incubation.
- the pH fell to 6.30 after 4 hours of incubation, then rose slightly to ⁇ 6.4 after 21 hours of incubation ( FIG. 3 ).
- Salivary sediment containing 90 or 120 mM valine in addition to 28 mM urea showed a rise in pH to 8.90 (90 mM valine) or 8.80 (120 mM valine) after 4 hours of incubation, falling slightly to 8.85 (90 mM valine) or 8.70 (120 mM valine) after 21 hours of incubation.
- the pH fell to ⁇ 6.3-6.5 after 4 hours of incubation, then rose to ⁇ 6.4-6.7 after 21 hours of incubation ( FIG. 4 ).
- Salivary sediment containing 90 or 120 mM histidine in addition to 28 mM urea showed a rise in pH from neutrality to 8.30 after 4 hours of incubation, remaining at 8.30 (90 mM histidine) or falling slightly to 8.22 (120 mM histidine) after 21 hours of incubation.
- the pH fell to ⁇ 6.92-7.00 after 4 hours of incubation, then rose to 7.20 after 21 hours of incubation ( FIG. 5 ).
- Salivary sediment containing 9 mM leucine in addition to 28 mM urea showed a rise in pH from neutrality to 8.85 after 4 hours of incubation, falling to 8.60 after 21 hours of incubation.
- salivary sediment containing 9 mM isoleucine in addition to 28 mM urea showed a rise in pH from neutrality to 8.90 after 4 hours of incubation, falling to 8.65 after 21 hours of incubation.
- salivary sediment containing leucine but without urea the pH fell to 6.15 after 4 hours of incubation, then rose to 6.40 after 21 hours of incubation.
- salivary sediment containing isoleucine but without urea the pH fell to 6.40 after 4 hours of incubation, then rose to 6.62 after 21 hours of incubation ( FIG. 6 ).
- Salivary sediment containing 9 mM aspartic acid in addition to 28 mM urea showed a rise in pH to 8.90 after 4 hours of incubation, falling to 8.60 after 21 hours of incubation.
- salivary sediment containing 9 mM glutamic acid in addition to 28 mM urea showed a rise in pH to 8.90 after 4 hours of incubation, falling to 8.50 after 21 hours of incubation.
- salivary sediment containing aspartic acid but without urea the pH remained at 7.00 after overnight incubation.
- salivary sediment containing glutamic acid but without urea the pH fell to 6.70 after overnight incubation ( FIG. 7 ).
- Salivary sediment containing 9 mM cystine or 9 mM cysteine in addition to 28 mM urea showed a rise in pH to 8.80 (cystine) or 8.75 (cysteine) after 4 hours of incubation, falling to 8.50 (cystine) or 8.55 (cysteine) after 21 hours of incubation.
- salivary sediment containing cysteine but without urea the pH fell to 6.35 after 4 hours of incubation, then rose to 6.60 after 21 hours of incubation ( FIG. 8 ).
- Salivary sediment containing 9 mM lysine or 9 mM arginine in addition to 28 mM urea showed a rise in pH to 8.70 (lysine) or 8.80 (arginine) after overnight incubation.
- the pH remained at neutrality after overnight incubation.
- salivary sediment containing arginine but without urea the pH rose to 7.97 after 21 hours of incubation ( FIG. 9 ).
- Salivary sediment containing 9 mM phenylalanine or 9 mM tyrosine in addition to 28 mM urea showed a rise in pH to 8.87 after 4 hours of incubation, falling to 8.65 (phenylalanine) or 8.62 (tyrosine) after overnight incubation ( FIG. 10 ).
- Salivary sediment containing 9 mM threonine or 9 mM proline in addition to 28 mM urea showed a rise in pH to 8.90 (threonine) or 9.00 (proline) after 4 hours of incubation, falling to 8.60 (threonine) or 8.80 (proline) after overnight incubation.
- the pH fell to 6.20 (threonine) or 6.10 (proline) after 4 hours of incubation, then remained about unchanged after 21 hours of incubation ( FIG. 11 ).
- Salivary sediment containing 9 mM methionine or 9 mM tryptophan in addition to 28 mM urea showed a rise in pH to 9.00 after 4 hours of incubation, falling slightly to 8.90 after overnight incubation.
- salivary sediment containing methionine or tryptophan but without urea the pH fell to 6.20 after overnight incubation ( FIG. 12 ).
- Salivary sediment containing 9 mM glutamine in addition to 28 mM urea showed a rise in pH to 9.00 after 4 hours of incubation, falling to 8.80 after overnight incubation.
- salivary sediment containing glutamine but without urea the pH fell to 5.95 after 4 hours of incubation, then rose to 6.25 after 21 hours of incubation ( FIG. 13 ).
- Salivary sediment containing 9 mM asparagine in addition to 28 mM urea showed a rise in pH to 8.90 after 4 hours of incubation, falling to 8.70 after 21 hours of incubation.
- salivary sediment containing asparagine but without urea the pH fell to 6.55 after 4 hours of incubation, then rose to 7.35 after overnight incubation ( FIG. 13 ).
- Salivary sediment containing 6.70 mM serine in addition to 6.70 mM urea showed a rise in pH to 7.60 after 21 hours of incubation.
- salivary sediment containing 6.70 mM serine but without urea the pH fell to 5.95 after 4 hours of incubation, then rose to 6.30 after 21 hours of incubation ( FIG. 14 ).
- salivary sediment containing 8.30 mM serine in addition to 6.70 mM urea showed a rise in pH to 7.50 after 21 hours of incubation.
- salivary sediment containing 8.30 mM serine but without urea the pH fell to 5.90 after 4 hours of incubation, then rose to 6.25 after 21 hours of incubation ( FIG. 14 ).
- salivary sediment containing 20 mM serine and 3 mM sodium phytate showed very little change from neutrality even with 6.70 mM urea.
- a similar pH pattern was observed with salivary sediment containing 25 mM serine, 3 mM sodium phytate, and 6.70 mM urea.
- salivary sediment containing 20 mM serine showed a pH drop to 6.20 from an initial pH of 6.90 after 4 hours of incubation; then, at 21 hours, it rose to 6.65.
- salivary sediment containing 25 mM serine showed a pH drop to 6.17 from an initial pH of 7.00 after 4 hours of incubation; then, at 21 hours, it rose to 6.70 ( FIG. 15 ).
- salivary sediment containing 20 or 25 mM serine and 6 mM sodium phytate showed very little change from neutrality even with 6.70 mM urea.
- salivary sediment containing 20 mM serine showed a pH drop to 7.15 (and salivary sediment containing 25 mM serine showed a pH drop to 6.17) after 4 hours of incubation; then, at 21 hours, it rose to 6.47 (20 mM serine) or 6.45 (25 mM serine) ( FIG. 16 ).
- the initial supernatant calcium level was 21.58 ⁇ g/ml for the mixture containing serine, sodium phytate, urea, and exposed enamel of a tooth piece, which gradually rose to 44.80 ⁇ g/ml after overnight incubation.
- the same incubation mixture without the exposed enamel of a tooth piece showed an initial supernatant calcium level of 19.74 ⁇ g/ml, which gradually rose to 33.11 ⁇ g/ml by the end of the incubation.
- the initial supernatant calcium level was 20.15 ⁇ g/ml, which rose to 73.87 ⁇ g/ml after 21 hours of incubation.
- the incubation mixture containing serine and sodium phytate showed an initial supernatant calcium level of 21.08 ⁇ g/ml, which rose to 43.30 ⁇ g/ml at the end of the incubation ( FIG. 19 ).
- the initial supernatant calcium level was 20.65 ⁇ g/ml for the mixture containing serine, sodium phytate, urea, and exposed cementum of a tooth piece, which rose to 41.30 ⁇ g/ml after 21 hours of incubation.
- the same incubation mixture without the exposed tooth cementum showed an initial supernatant calcium level of 17.83 ⁇ g/ml, which rose to 33.94 ⁇ g/ml by the end of the incubation.
- the initial supernatant calcium level was 22.65 ⁇ g/ml, which rose to 69.31 ⁇ g/ml after 21 hours of incubation.
- sodium phytate showed an initial supernatant calcium level of 17.00 ⁇ g/ml, which rose to 34.77 ⁇ g/ml at the end of the incubation ( FIG. 21 ).
- compositions and methods described herein include the manufacture and use of pharmaceutical compositions and medicaments that include one or more bivalent compounds as disclosed herein. Also included are the pharmaceutical compositions themselves.
- compositions disclosed herein can include other compounds, drugs, or agents used for the treatment of plaque and/or periodontal disease.
- pharmaceutical compositions disclosed herein can be combined with one or more (e.g., one, two, three, four, five, or less than ten) compounds.
- serine- and phosphate salt-containing compositions disclosed herein can operate in conjunction with other agents used for the treatment of plaque and/or periodontal disease to produce mechanistically additive or synergistic therapeutic effects.
- the pH of the compositions disclosed herein can be adjusted with pharmaceutically acceptable acids, bases, or buffers.
- the pH of the compositions disclosed herein is optimally in the range of about 6.0 to about 9.5, preferably in the range of about 6.1 to about 7.0 (e.g., about 6.1 to about 6.3 or about 6.7 to about 7.0).
- compositions typically include a pharmaceutically acceptable carrier, adjuvant, or vehicle.
- pharmaceutically acceptable refers to molecular entities and compositions that are generally believed to be physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human.
- a pharmaceutically acceptable carrier, adjuvant, or vehicle is a composition that can be administered to a patient, together with a compound of the invention, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound.
- Exemplary conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles include saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
- pharmaceutically acceptable carriers, adjuvants, and vehicles that can be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d- ⁇ -tocopherol polyethylene glycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, poly(S
- the serine- and phosphate salt-containing compositions disclosed herein are defined to include pharmaceutically acceptable derivatives or prodrugs thereof.
- a “pharmaceutically acceptable derivative” means any pharmaceutically acceptable salt, solvate, or prodrug, e.g., carbamate, ester, phosphate ester, salt of an ester, or other derivative of a compound or agent disclosed herein, which upon administration to a recipient is capable of providing (directly or indirectly) a compound described herein, or an active metabolite or residue thereof.
- Preferred derivatives and prodrugs include derivatives where a group that enhances aqueous solubility is appended to the structure of formulae described herein. Such derivatives are recognizable to those skilled in the art without undue experimentation. Nevertheless, reference is made to the teaching of Burger's Medicinal Chemistry and Drug Discovery, 5 th Edition, Vol. 1: Principles and Practice, which is incorporated herein by reference to the extent of teaching such derivatives.
- the serine- and phosphate salt-containing compositions disclosed herein include pure enantiomers, mixtures of enantiomers, pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates and the meso-form and pharmaceutically acceptable salts, solvent complexes, morphological forms, or deuterated derivative thereof.
- pharmaceutically acceptable salts of serine- and phosphate salt-containing compositions disclosed herein include, e.g., those derived from pharmaceutically acceptable inorganic and organic acids and bases.
- suitable acid salts include acetate, adipate, benzoate, benzenesulfonate, butyrate, citrate, digluconate, dodecylsulfate, formate, fumarate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, palmoate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, tartrate, tosylate, trifluoromethylsulfonate, and undecanoate.
- Salts derived from appropriate bases include, e.g., alkali metal (e.g., sodium), alkaline earth metal (e.g., magnesium), ammonium and N-(alkyl)4+ salts.
- alkali metal e.g., sodium
- alkaline earth metal e.g., magnesium
- ammonium e.g., ammonium
- N-(alkyl)4+ salts e.g., sodium
- alkaline earth metal e.g., magnesium
- ammonium e.g., sodium
- N-(alkyl)4+ salts e.g., sodium
- alkali metal e.g., sodium
- alkaline earth metal e.g., magnesium
- ammonium e.g., sodium
- N-(alkyl)4+ salts e.g., ammonium and N-(alkyl)4+ salts.
- the invention also envisions the quaternization of any basic nitrogen-
- the pharmaceutical compositions disclosed herein can include an effective amount of serine and/or one or more phosphate salts.
- effective amount and “effective to treat,” as used herein, refer to an amount or a concentration of one or more compounds or a pharmaceutical composition described herein utilized for a period of time (including acute or chronic administration and periodic or continuous administration) that is effective within the context of its administration for causing an intended effect or physiological outcome (e.g., treatment or prevention of plaque or periodontal disease).
- pharmaceutical compositions can further include one or more additional compounds, drugs, or agents used for the treatment of plaque and/or periodontal disease in amounts effective for causing an intended effect or physiological outcome (e.g., treatment or prevention of plaque or periodontal disease).
- compositions disclosed herein can be formulated or adapted for administration to a subject via any oral route, e.g., any oral route approved by the Food and Drug Administration (FDA).
- FDA Food and Drug Administration
- Exemplary methods are described in the FDA Data Standards Manual (DSM) (available at http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/DataStandardsManualmonographs).
- compositions of this invention can be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets (e.g., confections such as (soft) chewable tablets), emulsions and aqueous suspensions, dispersions, pastes or powders (e.g., dentifrices or toothpastes), gums (e.g., chewing gums), and solutions (e.g., mouthwashes or other rinses).
- carriers which are commonly used include lactose and corn starch.
- Lubricating agents such as magnesium stearate, are also typically added.
- useful diluents include lactose and dried corn starch.
- the active ingredient may be suspended or dissolved in an oily phase combined with emulsifying or suspending agents. If desired, certain sweetening, flavoring, or coloring agents can be added.
- an effective dose of a pharmaceutical composition of this invention can include, but is not limited to, e.g., about 0.00001, 0.0001, 0.001, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.25, 1.5, 1.75, 2, 2.5, or 3-10,000 mg/kg/day serine and/or one or more phosphate salts, or according to the requirements of the particular pharmaceutical composition.
- both the compound and the additional compound should be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen.
- the additional agents can be administered separately, as part of a multiple dose regimen, from the compounds of this invention. Alternatively, those agents can be part of a single dosage form, mixed together with the compounds of this invention in a single composition.
- compositions disclosed herein can be included in a container, pack, or dispenser together with instructions for administration.
- compositions comprising serine and/or one or more phosphate salts, including pharmaceutical compositions (indicated below as ‘X’) disclosed herein in the following methods:
- Substance X for use as a medicament in the treatment of one or more diseases or conditions disclosed herein e.g., plaque, referred to in the following examples as ‘Y’).
- the methods disclosed include the administration of a therapeutically effective amount of one or more of the compounds or compositions described herein to a subject (e.g., a mammalian subject, e.g., a human subject) who is in need of, or who has been determined to be in need of, such treatment.
- a subject e.g., a mammalian subject, e.g., a human subject
- the methods disclosed include selecting a subject and administering to the subject an effective amount of one or more of the compounds or compositions described herein, and optionally repeating administration as required for the prevention or treatment of plaque and/or periodontal disease.
- subject selection can include obtaining a sample from a subject (e.g., a candidate subject) and testing the sample for an indication that the subject is suitable for selection.
- the subject can be confirmed or identified, e.g. by a health care professional, as having had or having a condition or disease (e.g., periodontal disease).
- suitable subjects include, for example, subjects who have or had a condition or disease but that resolved the disease or an aspect thereof, present reduced symptoms of disease (e.g., relative to other subjects (e.g., the majority of subjects) with the same condition or disease), or that survive for extended periods of time with the condition or disease (e.g., relative to other subjects (e.g., the majority of subjects) with the same condition or disease), e.g., in an asymptomatic state (e.g., relative to other subjects (e.g., the majority of subjects) with the same condition or disease).
- exhibition of a positive immune response towards a condition or disease can be made from patient records, family history, or detecting an indication of a positive immune response.
- multiple parties can be included in subject selection.
- a first party can obtain a sample from a candidate subject and a second party can test the sample.
- subjects can be selected or referred by a medical practitioner (e.g., a general practitioner).
- subject selection can include obtaining a sample from a selected subject and storing the sample or using the sample in the methods disclosed herein. Samples can include, e.g., plaque or saliva.
- methods of treatment can include a single administration, multiple administrations, and repeating administration of one or more compounds disclosed herein as required for the prevention or treatment of the disease or condition from which the subject is suffering (e.g., periodontal disease).
- methods of treatment can include assessing a level of disease in the subject prior to treatment, during treatment, or after treatment. In some aspects, treatment can continue until a decrease in the level of disease in the subject is detected.
- subject refers to any animal. In some instances, the subject is a mammal. In some instances, the term “subject,” as used herein, refers to a human (e.g., a man, a woman, or a child).
- administer refers to orally administering a compound or composition, regardless of form.
- methods disclosed herein include administration of an effective amount of a compound or composition to achieve the desired or stated effect.
- compositions disclosed herein can optionally be administered to the oral cavity or specific portions of the oral cavity (e.g., one or more teeth, or one or more portions of one or more teeth (e.g., exposed enamel, dentine, or cementum)) using one or more devices known in the art, e.g., brushes (e.g., toothbrushes), floss or flossers (e.g., dental floss), irrigators (e.g., oral irrigators), picks (e.g., dental picks or toothpicks), scrapers (e.g., tongue cleaners or scrapers), spatulas, sticks, retainers or mouth guards, etc.
- brushes e.g., toothbrushes
- floss or flossers e.g., dental floss
- irrigators e.g., oral irrigators
- picks e.g., dental picks or toothpicks
- scrapers e.g., tongue cleaners or scrapers
- spatulas sticks, retainers or mouth guards, etc
- treat refers to partially or completely alleviating, inhibiting, ameliorating, or relieving the disease or condition from which the subject is suffering. This means any manner in which one or more of the symptoms of a disease or disorder (e.g., plaque or periodontal disease) are ameliorated or otherwise beneficially altered.
- amelioration of the symptoms of a particular disorder refers to any lessening, whether permanent or temporary, lasting or transient that can be attributed to or associated with treatment by the compositions and methods of the present invention.
- treatment can promote or result in, for example, a decrease in amount of plaque (e.g., in a subject) relative to the amount of plaque prior to treatment; or reductions in one or more symptoms associated with one or more periodontal diseases (e.g., gingivitis) in a subject relative to the subject's symptoms prior to treatment.
- a decrease in amount of plaque e.g., in a subject
- a periodontal diseases e.g., gingivitis
- prevent shall refer to a decrease in the occurrence of a disease or decrease in the risk of acquiring a disease or its associated symptoms in a subject.
- the prevention may be complete, e.g., the total absence of disease in a subject.
- the prevention may also be partial, such that the occurrence of the disease in a subject is less than, occurs later than, or develops more slowly than that which would have occurred without the present invention.
- Specific dosage and treatment regimens for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the disease, condition or symptoms, the patient's disposition to the disease, condition or symptoms, and the judgment of the treating physician.
- An effective amount can be administered in one or more administrations, applications or dosages.
- a therapeutically effective amount of a therapeutic compound depends on the therapeutic compounds selected.
- treatment of a subject with a therapeutically effective amount of the compounds or compositions described herein can include a single treatment or a series of treatments.
- effective amounts can be administered at least once.
- the compositions can be administered one from one or more times per day to one or more times per week; including once every other day. The skilled artisan will appreciate that certain factors can influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health or age of the subject, and other diseases present.
- the subject can be evaluated to detect, assess, or determine their level of disease.
- treatment can continue until a change (e.g., reduction) in the level of disease in the subject is detected.
- a maintenance dose of a compound, or composition disclosed herein can be administered, if necessary.
- the dosage or frequency of administration, or both can be reduced, e.g., as a function of the symptoms, to a level at which the improved condition is retained.
- Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
- amino acids that comprise the bulk of the amino acids found in humans were tested for their potential effects on intra-oral pH. These amino acids included: glycine, alanine, glutamic acid, glutamine, aspartic acid, valine, histidine, leucine, isoleucine, cystine, cysteine, arginine, lysine, phenylalanine, serine, tyrosine, threonine, proline, methionine, tryptophan, and asparagine. Samples of each amino acid were obtained (Sigma-Aldrich, St. Louis, Mo.) for study of their acidic and alkalinic tendencies within the human oral cavity, as it relates to elements of periodontitis pathology (e.g., dental caries, dental calculus, and gingivitis).
- Periodontitis pathology e.g., dental caries, dental calculus, and gingivitis
- paraffin wax (4.02 g) was chewed by human subjects (including some subjects 70+ years of age, where oral alkalinity is commonly more prevalent) to stimulate the flow of saliva. Prior to the experiment, the subjects fasted for 12 hours and abstained from oral hygiene for at least 24 hours (to enable spontaneous dental plaque bacterial growth and buildup on their teeth and other oral surfaces (Kleinberg. I., 1967, Arch. Oral Biol., 1457-1473)). As a result of this process, oral bacteria were dislodged by the inert paraffin wax from the teeth and oral soft tissue surfaces in the mouths of the human subjects.
- the saliva collected was centrifuged at 1740 g in an International Equipment Company clinical centrifuge (Needham Heights, Mass.) for 15 min. at 4° C. The supernatant was decanted and discarded.
- 40 ml of ice-cold distilled water was added and mixed in a vortex mixer.
- the resulting sediment-water mixture was centrifuged at 1740 g for 15 min. at 4° C.
- the supernatant was again decanted and discarded.
- This bacterial sediment washing procedure was repeated twice.
- 10 ml of deionized water was added and the composition was then mixed briefly and thoroughly in a vortex mixer. The sediment was transferred to a 15 ml polypropylene centrifuge tube.
- the resulting suspension was centrifuged at 1740 g for 15 min. at 4° C. and the resulting supernatant was aspirated and discarded.
- salivary sediment obtained after centrifugation, 1.0 ml of de-ionized water was added to make a 50% salivary sediment suspension for the preparation of the following standard incubation mixtures: salivary sediment at 16.7% (v/v), with and without added individual amino acids: serine, glycine, alanine, valine, and/or histidine, etc.
- the initial pH of the incubation mixtures was carefully adjusted to or near 7.0 with either 1.0 M NaOH or 1.0 M HCl. Each bacterial mixture was then incubated overnight in a water bath at 37° C. The pH of each mixture was then determined using a combined pH and reference electrode (Radiometer Analytical SAS, Villeurbanne, France) at pre-determined time intervals.
- incubation mixtures containing salivary sediment at 16.7% (v/v), 20 or 25 mM serine, and 6 mM sodium phytate were prepared in the presence or absence of 6.7 mM urea. Mixtures were incubated overnight at 37° C. in a water bath incubator, after adjusting the initial pH to or near 7.0 with 1N NaOH or 1N HCl.
- incubation mixtures containing salivary sediment at 16.7% (v/v), 238 mM serine, and 6 mM sodium phytate were prepared in the presence or absence of 6.7 mM urea. Mixtures were incubated overnight at 37° C. in a water bath incubator, after adjusting the initial pH to or near 7.0 with 1N NaOH or 1N HCl.
- incubation mixtures were prepared containing a sample of human molar tooth (e.g., enamel crown with undesirable exposed dentin covered by and hence painted over with inert nail polish ( FIG. 23 )), along with salivary sediment at 16.7% (v/v), 238 mM serine, and 6.0 mM sodium phytate, optionally with one or more other amino acids at the concentrations recited above, in the presence or absence of 6.7 mM urea.
- Aliquots (200 ⁇ l) from each incubation mixture were withdrawn at 0, 1, 2, 4, and 21 hours of incubation and centrifuged at 10,000 g for 10 min. at 4° C.
- Supernatants were stored at ⁇ 20° C. for subsequent analysis of calcium by atomic absorption spectroscopy 3110 (PerkinElmer, Norwalk, Conn.).
- Similar incubation mixtures were also prepared containing a sample of tooth cementum (e.g., from the roots of human molar teeth ( FIG. 24 )).
- the tooth coronal surfaces were partially covered with inert nail polish (Sally Hanson, Del Laboratory Inc., Garden City, N.Y.), and then prepared and incubated in similar fashion described above for the mixtures containing a sample of human molar tooth.
- Aliquots (200 ⁇ l) from each incubation mixture were withdrawn at 0, 1, 2, 4, and 21 hours of incubation and centrifuged at 10,000 g for 10 min. at 4° C.
- Supernatants were stored at ⁇ 20° C. for subsequent analysis of calcium by atomic absorption spectroscopy 3110 (PerkinElmer, Norwalk, Conn.).
- incubation mixtures containing salivary sediment at 16.7% (v/v), 238 mM serine, and 6 mM sodium phytate, with or without 6.7 mM urea were prepared and incubated without adjusting the initial pH to or near 7.0, except for salivary sediment mixed with de-ionized water, which was adjusted to pH 8.10 with 1 M NaOH.
- Determination of the pH of each of these experimental entities were carried out at pre-determined time intervals (i.e., at 0 min., 15 min., 30 min., 1 h, 2 h, 3 h, 4 h, and 21 h) with a pH meter (Radiometer Copenhagen, type PHM26, Radiometer America, Westlake, Ohio) and a combination pH electrode (Radiometer Analytical, Cedex, France).
- a pH meter Radiometer Copenhagen, type PHM26, Radiometer America, Westlake, Ohio
- a combination pH electrode Radiometer Analytical, Cedex, France
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Remote Sensing (AREA)
- Aviation & Aerospace Engineering (AREA)
- Chemical & Material Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Combustion & Propulsion (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Sustainable Energy (AREA)
- Sustainable Development (AREA)
- Toxicology (AREA)
- Environmental Sciences (AREA)
- Environmental & Geological Engineering (AREA)
- Biodiversity & Conservation Biology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Photovoltaic Devices (AREA)
Abstract
Compositions comprising serine and an organic mono- or multi-phosphate salt and methods of using such compositions to treat and/or prevent periodontal disease and/or dental calculus are provided.
Description
- This application is a continuation of U.S. application Ser. No. 15/587,265, filed May 4, 2017 which claims the benefit of U.S. Provisional Application No. 62/332,201 filed May 5, 2016, the contents of which are incorporated herewith.
- This disclosure relates to compositions comprising serine and an organic mono- or multi-phosphate salt (e.g., a phytate) for the treatment and/or prevention of periodontitis (e.g., gingivitis) and/or dental calculus formation or development.
- The human oral cavity contains one of the most densely populated and complex mixed microbial floras that inhabit the human body (Takhashi, N., 2005). One major component of the oral mixed microbial flora is comprised of fermentable carbohydrate metabolizing types of microorganisms that are found particularly in supra-gingival dental sites, namely tooth pits, fissures, and interproximal tooth embrasures. Fermentable dietary carbohydrates and corresponding fermentative oral bacteria are easily and regularly retained in many of these intra-oral locations, sheltered from saliva and readily able to interact to produce abundant acidity and an acidic pH. Such acidity is principally due to the generation of lactic acid, an entity that can readily solubilize tooth calcium phosphate, the dominant mineral element comprising the mineralized tissues (i.e., enamel, dentin, and cementum) of human teeth.
- In contrast to acidity, if the environment of the teeth gingivae is alkaline (e.g., because of elevated urea levels that occur in many individuals' gingival crevicular fluid), alkaline conditions may be expected to prevail around the necks of the teeth to where, instead of dental caries, dental calculus and/or periodontitis indices are more evident.
- The dental calculus/periodontitis entity involves a mixed microbial flora that mainly populates the regions around the necks of the teeth and extends into adjacent gingival and subgingival dentition sites. The bacteria involved in these locations are mainly non-fermenting. They have been proven to be largely comprised of proteolytic, putrefactive microorganisms that readily metabolize nitrogenous substrates, particularly such derived from the gingivae and adjacent gingival crevicular and periodontal pocket fluids and tissues (Takhashi, N., 2005). Of particular note is that this includes involvement with urea and amino acids, the main end-products of the numerous, common human body amino acids that circulate in the blood vessels throughout the human body. These amino acids and ammonia related thereto are degraded by enzymes in bacteria readily found in gingival crevicular fluid (Golub, L. M., Borden, S. M., and Kleinberg, I., 1971; Onosi, M., Tachibana, Y., Nakamura, T., Takakuwa, S., and Ishioka, K., 1957; Singer, D. L. and Kleinberg, I., 1978).
- Upon microbial degradation, gingival and periodontal crevices containing urea are conducive to bacterial degradation to ammonia and can exhibit a high alkaline pH. Such a high pH is an essential element responsible for the easy formation of calcium phosphate deposits (generally referred to as dental plaque or calculus), which readily form around the base of the crowns of teeth (Denepitiya L. and Kleinberg I., 1982; Arch. Oral Biol.; Salako, N. O. and Kleinberg, I., 1989; Jin, Y. and Yip, H.-K., 2002). Left untreated, these crevices promote the proliferation of additional ureolytic and proteolytic bacteria, which in turn promote the formation of additional calculus. Ultimately, this can cause the development of periodontal disease (e.g., gingivitis) (Jacobson, M. and Kesel, R. G., 1950). Central to these processes are the formation and flow of gingival/periodontal crevicular fluid (Golub, L. M., Borden, S. M., and Kleinberg, I., 1971), which characterizes and helps perpetuate these periodontal disease conditions by maintaining a high pH in the environment.
- We have previously shown that amino acids can serve as important bacterial substrates and can thereby help facilitate both the accumulation of dental plaque and the development of periodontal disease (including gingivitis, with symptoms including bleeding gums and putrefactive gingivae). For example, urea has been demonstrated to promote tooth and gingival alkalinity, enhancing the accumulation of plaque-causing bacteria on teeth and other surfaces in the oral cavity (Kleinberg, I., 1967, Arch. Oral Biol., 1475-1484). Numerous other amino acids can serve as nitrogenous substrates that contribute to varying degrees of alkalinity and promote periodontal disease, albeit to a lesser degree than urea (Biswas, S. D. and Kleinberg, I., 1971; Golub, L. M., Borden, S. M., and Kleinberg, I., 1971; Kleinberg, I. and Hall, G., 1968). In general, amino acids function to maintain a balance of alkalinity in the oral cavity.
- The present disclosure relates generally to compositions comprising serine and an organic mono- or multi-phosphate salt (e.g., a phytate) which can treat and/or prevent periodontal disease (e.g., gingivitis, e.g., by reducing gingival alkalinity), and/or treat and/or prevent dental calculus accumulation, formation, and/or development.
- More specifically, the present disclosure provides an oral composition including serine and one or more organic mono-phosphate or multi-phosphate salts, wherein the pH of the composition is between about 6.0 and about 9.5. The pH of the composition can be, e.g., between about 6.1 and about 6.3. The pH of the composition can be, e.g., between about 6.7 and about 7.0. The organic mono-phosphate or multi-phosphate salts can include, e.g., one or more biological salts. The biological salts can include, e.g., one or more inositol (e.g., phytate) salts. The phytates can include, e.g., sodium phytate. The composition can include, e.g., serine phytate.
- Any of the above oral compositions can be provided in an orally acceptable dosage form. The orally acceptable dosage form can be, e.g., a chewable tablet, a piece of chewing gum, a dentifrice, a mouthwash, a rinse, and/or a toothpaste.
- Any of the above oral compositions can include one or more devices. One or more surfaces of the device can include, e.g., serine and one or more organic mono-phosphate or multi-phosphate salts, wherein the pH of the surface is between about 6.0 and about 9.5. The pH of the surface can be, e.g., between about 6.1 and about 6.3. The pH of the surface can be, e.g., between about 6.7 and about 7.0. The organic mono-phosphate or multi-phosphate salts can include, e.g., one or more biological salts. The biological salts can include, e.g., one or more inositols (e.g., phytates). The phytates can include, e.g., sodium phytate. The composition can include, e.g., serine phytate. The device can be, e.g., a brush, a piece of floss, a flosser, an irrigator, a mouth guard, a pick, a retainer, a scraper, a spatula, and/or a stick.
- The document also provides a method of treating or preventing plaque or periodontal disease (e.g., gingivitis), the method comprising administering an effective amount of any of the above oral compositions to a subject (e.g., a human) having, or at risk of having, plaque or periodontal disease. The oral composition can be, e.g., applied to one or more teeth (e.g., the exposed enamel, dentine, and/or cementum of one or more teeth) of the subject.
- The terms “periodontal disease” and “periodontitis” are used interchangeably herein, and refer to one or more periodontal (gum) diseases in an oral cavity (e.g., gingivitis).
- The terms “plaque” and “calculus” are used interchangeably herein, and refer to dental plaque or calculus on one or more hard (e.g., teeth) or soft (e.g., mucosal tissue) surfaces in an oral cavity.
- As used herein, the term “overnight” is defined as being about 21 hours.
- As used herein, the terms “about” and “approximately” are defined as being within plus or minus 10% of a given value or state, preferably within plus or
minus 5% of said value or state. - Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Methods and materials are described herein for use in the present invention; other, suitable methods and materials known in the art can also be used. The materials, methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.
- Other features and advantages of the invention will be apparent from the following detailed description and figures, and from the claims.
-
FIG. 1 is a graph showing the pH response of salivary sediment with or without serine, urea, or a mixture of serine and urea. -
FIG. 2 is a graph showing the pH response of salivary sediment with or without glycine, urea, or a mixture of glycine and urea. -
FIG. 3 is a graph showing the pH response of salivary sediment with or without alanine, urea, or a mixture of alanine and urea. -
FIG. 4 is a graph showing the pH response of salivary sediment with or without valine, urea, or a mixture of valine and urea. -
FIG. 5 is a graph showing the pH response of salivary sediment with or without histidine, urea, or a mixture of histidine and urea. -
FIG. 6 is a graph showing the pH response of salivary sediment with or without leucine, isoleucine, urea, or a mixture of leucine and urea or isoleucine and urea. -
FIG. 7 is a graph showing the pH response of salivary sediment with or without aspartic acid, glutamic acid, urea, or a mixture of aspartic acid and urea or glutamic acid and urea. -
FIG. 8 is a graph showing the pH response of salivary sediment with or without cystine, cysteine, urea, or a mixture of cystine and urea or cysteine and urea. -
FIG. 9 is a graph showing the pH response of salivary sediment with or without lysine, arginine, urea, or a mixture of lysine and urea or arginine and urea. -
FIG. 10 is a graph showing the pH response of salivary sediment with or without phenylalanine, tyrosine, urea, or a mixture of phenylalanine and urea or tyrosine and urea. -
FIG. 11 is a graph showing the pH response of salivary sediment with or without threonine, proline, urea, or a mixture of threonine and urea or proline and urea. -
FIG. 12 is a graph showing the pH response of salivary sediment with or without methionine, tryptophan, urea, or a mixture of methionine and urea or tryptophan and urea. -
FIG. 13 is a graph showing the pH response of salivary sediment with or without glutamine, asparagine, urea, or a mixture of glutamine and urea or asparagine and urea. -
FIG. 14 is a graph showing the pH response of salivary sediment with 6.7 or 8.3 mM serine, with or without urea. -
FIG. 15 is a graph showing the pH response of salivary sediment with 20 or 25 mM serine, with or without urea and 3 mM sodium phytate. -
FIG. 16 is a graph showing the pH response of salivary sediment with 20 or 25 mM serine, with or without urea and 6 mM sodium phytate. -
FIG. 17 is a graph showing the pH response of salivary sediment with 238 mM serine, with or without urea and 6 mM sodium phytate. -
FIG. 18 is a graph showing the pH response of salivary sediment with 238 mM serine and 6 mM sodium phytate, with or without urea and a piece of human tooth. -
FIG. 19 is a graph showing calcium release in an incubation mixture containing salivary sediment, serine, sodium phytate, and urea, with or without enamel from a human tooth. -
FIG. 20 is a graph showing the pH response of salivary sediment with 238 mM serine and 6 mM sodium phytate, with or without urea and a piece of human tooth cementum. -
FIG. 21 is a graph showing calcium release in an incubation mixture containing salivary sediment, serine, sodium phytate, and urea, with or without cementum from a human tooth. -
FIG. 22 is a graph showing the pH response of salivary sediment with 238 mM serine and 6 mM sodium phytate, with or without urea, when the initial pH was not adjusted to neutrality. -
FIG. 23 is a series of photographs showing a piece of a molar tooth. -
FIG. 24 is a photograph showing the roots of a molar tooth. - The present disclosure is based, in part, on the discovery that novel compositions comprising serine and an organic mono- or multi-phosphate salt (e.g., a biological salt such as a phytate) are useful in the treatment and/or prevention of periodontal disease (e.g., gingivitis, e.g., by reducing gingival alkalinity). The compositions disclosed herein are alternately or additionally useful in the treatment and/or prevention of plaque (e.g., by inhibiting, reducing, and/or reversing the accumulation, formation, and/or development of dental calculus).
- Multiple aspects of the physiology and pathology of the common amino acids found in the oral cavity and elsewhere in the human body were characterized. In particular, each amino acid was examined to determine whether and to what extent it could modulate the pH of the oral cavity. In light of the known alkalinity-promoting functions of amino acids such as arginine and urea in the oral cavity, it was surprisingly found that compositions comprising serine uniquely possess the ability, in the presence of salivary urea, to lower the pH from an alkaline level (i.e., >7.0) to about neutrality (i.e., about 7.0) or even (depending on arginine concentration) to a slightly acidic level (i.e., <7.0). Thus, serine-containing compositions can be used to counteract some of the undesirable alkalinity generated by the catabolism of urea and other nitrogen-containing entities by bacteria in the oral cavity.
- Without wishing to be bound by theory, the addition of a serine-containing composition to saliva provides serine as a “pH-fall” factor, as it causes a reduction in pH when converted from serine to cysteine to pyruvate to lactate by bacteria in the oral cavity. Without wishing to be bound by theory, altering the pH of the oral cavity using such a composition can help promote the dominance of saccharidic microorganisms in subgingival dental plaque over asaccharidic microorganisms, thus reducing the overall accumulation and formation of dental calculus. Such serine-containing compositions are also useful in treating and preventing periodontal disease.
- It was found that the effectiveness of such serine-containing compositions can be further improved by the addition of one or more organic mono- or multi-phosphate salts (e.g., a biological salt such as an inositol salt (e.g., an inositol monophosphate salt, an inositol pentaphosphate salt, or an inositol hexaphosphate (a.k.a., phytate) salt such as sodium phytate and potassium phytate). Phytates are phosphate anions with phosphate groups that readily form complexes with calcium ions, complexes easily solubilized in aqueous solutions (e.g., saliva). Without wishing to be bound by theory, the phosphate anions present on phytates and other organic mono- or multi-phosphate salts can serve as carriers in binding to and solubilizing free calcium ions (thereby effectively removing them from saliva) and thus inhibiting the overall accumulation and formation of dental plaque.
- As expected, salivary sediment containing 28 mM urea showed a significant rise in pH from neutrality to about 9.0 after 4 hours of incubation at 37° C. (
FIG. 1 ). The pH remained about the same (dropping slightly to 8.8) after 21 hours of incubation at 37° C. In contrast, salivary sediment containing 90 or 120 mM serine in addition to 28 mM urea showed a significantly smaller increase in pH, from neutrality to 8.22 (90 mM serine) or 8.30 (120 mM serine) after 4 hours of incubation at 37° C. After 21 hours of incubation at 37° C., the pH dropped significantly, to 7.85. - In a similar assay, the pH of salivary sediment containing 90 or 120 mM serine, but without urea, dropped from neutrality to about 6.0 after 4 hours of incubation at 37° C., then rose to ˜6.6-6.8 after 21 hours of incubation at 37° C.
- Unless otherwise specified, all incubation steps described below were at 37° C.
- Salivary sediment containing 90 or 120 mM glycine in addition to 28 mM urea showed a rise in pH from neutrality to 8.72 (90 mM glycine) or 8.90 (120 mM glycine) after 4 hours of incubation, falling to 8.65 (90 mM glycine) or 8.55 (120 mM glycine) after 21 hours of incubation. In salivary sediment containing glycine but without urea, the pH fell from 6.80 to ˜6.40 after 4 hours of incubation, then rose to ˜7.0-7.15 after 21 hours of incubation (
FIG. 2 ). - Salivary sediment containing 90 or 120 mM alanine in addition to 28 mM urea showed a rise in pH from neutrality to 8.82 (90 mM alanine) or 8.72 (120 mM alanine) after 4 hours of incubation, falling slightly to 8.80 (90 mM alanine) or 8.67 (120 mM alanine) after 21 hours of incubation. In salivary sediment containing alanine but without urea, the pH fell to 6.30 after 4 hours of incubation, then rose slightly to ˜6.4 after 21 hours of incubation (
FIG. 3 ). - Salivary sediment containing 90 or 120 mM valine in addition to 28 mM urea showed a rise in pH to 8.90 (90 mM valine) or 8.80 (120 mM valine) after 4 hours of incubation, falling slightly to 8.85 (90 mM valine) or 8.70 (120 mM valine) after 21 hours of incubation. In salivary sediment containing valine but without urea, the pH fell to ˜6.3-6.5 after 4 hours of incubation, then rose to ˜6.4-6.7 after 21 hours of incubation (
FIG. 4 ). - Salivary sediment containing 90 or 120 mM histidine in addition to 28 mM urea showed a rise in pH from neutrality to 8.30 after 4 hours of incubation, remaining at 8.30 (90 mM histidine) or falling slightly to 8.22 (120 mM histidine) after 21 hours of incubation. In salivary sediment containing histidine but without urea, the pH fell to ˜6.92-7.00 after 4 hours of incubation, then rose to 7.20 after 21 hours of incubation (
FIG. 5 ). - Salivary sediment containing 9 mM leucine in addition to 28 mM urea showed a rise in pH from neutrality to 8.85 after 4 hours of incubation, falling to 8.60 after 21 hours of incubation. Similarly, salivary sediment containing 9 mM isoleucine in addition to 28 mM urea showed a rise in pH from neutrality to 8.90 after 4 hours of incubation, falling to 8.65 after 21 hours of incubation. In salivary sediment containing leucine but without urea, the pH fell to 6.15 after 4 hours of incubation, then rose to 6.40 after 21 hours of incubation. In salivary sediment containing isoleucine but without urea, the pH fell to 6.40 after 4 hours of incubation, then rose to 6.62 after 21 hours of incubation (
FIG. 6 ). - Salivary sediment containing 9 mM aspartic acid in addition to 28 mM urea showed a rise in pH to 8.90 after 4 hours of incubation, falling to 8.60 after 21 hours of incubation. Similarly, salivary sediment containing 9 mM glutamic acid in addition to 28 mM urea showed a rise in pH to 8.90 after 4 hours of incubation, falling to 8.50 after 21 hours of incubation. In salivary sediment containing aspartic acid but without urea, the pH remained at 7.00 after overnight incubation. In salivary sediment containing glutamic acid but without urea, the pH fell to 6.70 after overnight incubation (
FIG. 7 ). - Salivary sediment containing 9 mM cystine or 9 mM cysteine in addition to 28 mM urea showed a rise in pH to 8.80 (cystine) or 8.75 (cysteine) after 4 hours of incubation, falling to 8.50 (cystine) or 8.55 (cysteine) after 21 hours of incubation. In salivary sediment containing cystine but without urea, the pH fell to 6.35 after overnight incubation. In salivary sediment containing cysteine but without urea, the pH fell to 6.35 after 4 hours of incubation, then rose to 6.60 after 21 hours of incubation (
FIG. 8 ). - Salivary sediment containing 9 mM lysine or 9 mM arginine in addition to 28 mM urea showed a rise in pH to 8.70 (lysine) or 8.80 (arginine) after overnight incubation. In salivary sediment containing lysine but without urea, the pH remained at neutrality after overnight incubation. In salivary sediment containing arginine but without urea, the pH rose to 7.97 after 21 hours of incubation (
FIG. 9 ). - Salivary sediment containing 9 mM phenylalanine or 9 mM tyrosine in addition to 28 mM urea showed a rise in pH to 8.87 after 4 hours of incubation, falling to 8.65 (phenylalanine) or 8.62 (tyrosine) after overnight incubation (
FIG. 10 ). - Salivary sediment containing 9 mM threonine or 9 mM proline in addition to 28 mM urea showed a rise in pH to 8.90 (threonine) or 9.00 (proline) after 4 hours of incubation, falling to 8.60 (threonine) or 8.80 (proline) after overnight incubation. In salivary sediment containing threonine or proline but without urea, the pH fell to 6.20 (threonine) or 6.10 (proline) after 4 hours of incubation, then remained about unchanged after 21 hours of incubation (
FIG. 11 ). - Salivary sediment containing 9 mM methionine or 9 mM tryptophan in addition to 28 mM urea showed a rise in pH to 9.00 after 4 hours of incubation, falling slightly to 8.90 after overnight incubation. In salivary sediment containing methionine or tryptophan but without urea, the pH fell to 6.20 after overnight incubation (
FIG. 12 ). - Salivary sediment containing 9 mM glutamine in addition to 28 mM urea showed a rise in pH to 9.00 after 4 hours of incubation, falling to 8.80 after overnight incubation. In salivary sediment containing glutamine but without urea, the pH fell to 5.95 after 4 hours of incubation, then rose to 6.25 after 21 hours of incubation (
FIG. 13 ). - Salivary sediment containing 9 mM asparagine in addition to 28 mM urea showed a rise in pH to 8.90 after 4 hours of incubation, falling to 8.70 after 21 hours of incubation. In salivary sediment containing asparagine but without urea, the pH fell to 6.55 after 4 hours of incubation, then rose to 7.35 after overnight incubation (
FIG. 13 ). - Salivary sediment containing 6.70 mM serine in addition to 6.70 mM urea showed a rise in pH to 7.60 after 21 hours of incubation. In salivary sediment containing 6.70 mM serine but without urea, the pH fell to 5.95 after 4 hours of incubation, then rose to 6.30 after 21 hours of incubation (
FIG. 14 ). - Similarly, salivary sediment containing 8.30 mM serine in addition to 6.70 mM urea showed a rise in pH to 7.50 after 21 hours of incubation. In salivary sediment containing 8.30 mM serine but without urea, the pH fell to 5.90 after 4 hours of incubation, then rose to 6.25 after 21 hours of incubation (
FIG. 14 ). - The pH of salivary sediment containing 20 mM serine and 3 mM sodium phytate showed very little change from neutrality even with 6.70 mM urea. A similar pH pattern was observed with salivary sediment containing 25 mM serine, 3 mM sodium phytate, and 6.70 mM urea. In the absence of urea, salivary sediment containing 20 mM serine showed a pH drop to 6.20 from an initial pH of 6.90 after 4 hours of incubation; then, at 21 hours, it rose to 6.65. In the absence of urea, salivary sediment containing 25 mM serine showed a pH drop to 6.17 from an initial pH of 7.00 after 4 hours of incubation; then, at 21 hours, it rose to 6.70 (
FIG. 15 ). - The pH of salivary sediment containing 20 or 25 mM serine and 6 mM sodium phytate showed very little change from neutrality even with 6.70 mM urea. In the absence of urea, salivary sediment containing 20 mM serine showed a pH drop to 7.15 (and salivary sediment containing 25 mM serine showed a pH drop to 6.17) after 4 hours of incubation; then, at 21 hours, it rose to 6.47 (20 mM serine) or 6.45 (25 mM serine) (
FIG. 16 ). - The pH of salivary sediment containing 238 mM serine and 6 mM sodium phytate in addition to 6.70 mM urea showed a small rise in pH at the early stages of incubation, and dropped to 6.50 by 21 hours of incubation. In the absence of urea, the pH dropped to 6.00 after 4 hours of incubation; then, at 21 hours, it rose to 6.25 (
FIG. 17 ). - When a small block of tooth substance with only enamel exposed (
FIGS. 18 and 23 ) was incubated with a composition containing 238 mM serine, 6 mM sodium phytate, and 6.7 mM urea, the resulting mixtures showed a rise in pH to 7.30 from 7.00 at the early stages of incubation, and a drop in pH thereafter to 7.10. The pH profile of exactly the same incubation mixture without the tooth block added was more or less the same as the pH profile when the tooth block was present. In the absence of urea, with or without exposed enamel from a piece of tooth (FIG. 23 ), the incubation showed a pH fall for a period of four hours, which was then followed by a significant rise after overnight incubation (FIG. 18 ). - The initial supernatant calcium level was 21.58 μg/ml for the mixture containing serine, sodium phytate, urea, and exposed enamel of a tooth piece, which gradually rose to 44.80 μg/ml after overnight incubation. The same incubation mixture without the exposed enamel of a tooth piece showed an initial supernatant calcium level of 19.74 μg/ml, which gradually rose to 33.11 μg/ml by the end of the incubation. In the absence of urea in the incubation mixture containing serine, sodium phytate, and exposed enamel of a tooth piece, the initial supernatant calcium level was 20.15 μg/ml, which rose to 73.87 μg/ml after 21 hours of incubation. In the absence of urea and the absence of exposed enamel of a tooth piece, the incubation mixture containing serine and sodium phytate showed an initial supernatant calcium level of 21.08 μg/ml, which rose to 43.30 μg/ml at the end of the incubation (
FIG. 19 ). - Mixtures containing an exposed piece of tooth cementum (
FIG. 24 ), plus serine, sodium phytate, and urea, showed a pH profile of a slow rise from neutrality and a slow fall back to neutrality at the end of the incubation period. A similar pH pattern was observed for the same incubation mixture without the presence of the exposed piece of tooth cementum. In the absence of urea, mixtures containing an exposed piece of tooth cementum, plus serine and sodium phytate, showed a pH drop to 6.40 after 4 hours of incubation, then a rise to 6.55 after 21 hours of incubation. A similar pH pattern was observed for mixtures without both urea and an exposed piece of tooth cementum (FIG. 20 ). - The initial supernatant calcium level was 20.65 μg/ml for the mixture containing serine, sodium phytate, urea, and exposed cementum of a tooth piece, which rose to 41.30 μg/ml after 21 hours of incubation. The same incubation mixture without the exposed tooth cementum showed an initial supernatant calcium level of 17.83 μg/ml, which rose to 33.94 μg/ml by the end of the incubation. In the absence of urea in the incubation mixture containing serine, sodium phytate, and exposed cementum of a tooth piece, the initial supernatant calcium level was 22.65 μg/ml, which rose to 69.31 μg/ml after 21 hours of incubation. In the absence of urea and the absence of exposed cementum of a tooth piece, the incubation mixture containing serine and
- sodium phytate showed an initial supernatant calcium level of 17.00 μg/ml, which rose to 34.77 μg/ml at the end of the incubation (
FIG. 21 ). - When the initial pH of the incubation mixture containing salivary sediment, serine, and urea was not adjusted to pH 7.00 before incubation, the initial pH was 8.10, and the pH gradually fell to 6.85 by the end of the incubation. The same pH drop was observed in the absence of urea, except that the pH fell to 6.50 from an initial pH of 8.10 after 21 hours (
FIG. 22 ). - In some aspects, the compositions and methods described herein include the manufacture and use of pharmaceutical compositions and medicaments that include one or more bivalent compounds as disclosed herein. Also included are the pharmaceutical compositions themselves.
- In some aspects, the compositions disclosed herein can include other compounds, drugs, or agents used for the treatment of plaque and/or periodontal disease. For example, in some instances, pharmaceutical compositions disclosed herein can be combined with one or more (e.g., one, two, three, four, five, or less than ten) compounds. When co-administered, serine- and phosphate salt-containing compositions disclosed herein can operate in conjunction with other agents used for the treatment of plaque and/or periodontal disease to produce mechanistically additive or synergistic therapeutic effects.
- In some aspects, the pH of the compositions disclosed herein can be adjusted with pharmaceutically acceptable acids, bases, or buffers. The pH of the compositions disclosed herein is optimally in the range of about 6.0 to about 9.5, preferably in the range of about 6.1 to about 7.0 (e.g., about 6.1 to about 6.3 or about 6.7 to about 7.0).
- Pharmaceutical compositions typically include a pharmaceutically acceptable carrier, adjuvant, or vehicle. As used herein, the phrase “pharmaceutically acceptable” refers to molecular entities and compositions that are generally believed to be physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human. A pharmaceutically acceptable carrier, adjuvant, or vehicle is a composition that can be administered to a patient, together with a compound of the invention, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound. Exemplary conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles include saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
- In particular, pharmaceutically acceptable carriers, adjuvants, and vehicles that can be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-α-tocopherol polyethylene glycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat. Cyclodextrins such as α-, β-, and γ-cyclodextrin, may also be advantageously used to enhance delivery of compounds of the formulae described herein.
- As used herein, the serine- and phosphate salt-containing compositions disclosed herein are defined to include pharmaceutically acceptable derivatives or prodrugs thereof. A “pharmaceutically acceptable derivative” means any pharmaceutically acceptable salt, solvate, or prodrug, e.g., carbamate, ester, phosphate ester, salt of an ester, or other derivative of a compound or agent disclosed herein, which upon administration to a recipient is capable of providing (directly or indirectly) a compound described herein, or an active metabolite or residue thereof. Preferred derivatives and prodrugs include derivatives where a group that enhances aqueous solubility is appended to the structure of formulae described herein. Such derivatives are recognizable to those skilled in the art without undue experimentation. Nevertheless, reference is made to the teaching of Burger's Medicinal Chemistry and Drug Discovery, 5th Edition, Vol. 1: Principles and Practice, which is incorporated herein by reference to the extent of teaching such derivatives.
- The serine- and phosphate salt-containing compositions disclosed herein include pure enantiomers, mixtures of enantiomers, pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates and the meso-form and pharmaceutically acceptable salts, solvent complexes, morphological forms, or deuterated derivative thereof.
- In particular, pharmaceutically acceptable salts of serine- and phosphate salt-containing compositions disclosed herein include, e.g., those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acid salts include acetate, adipate, benzoate, benzenesulfonate, butyrate, citrate, digluconate, dodecylsulfate, formate, fumarate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, palmoate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, tartrate, tosylate, trifluoromethylsulfonate, and undecanoate.
- Salts derived from appropriate bases include, e.g., alkali metal (e.g., sodium), alkaline earth metal (e.g., magnesium), ammonium and N-(alkyl)4+ salts. The invention also envisions the quaternization of any basic nitrogen-containing groups of the serine- and phosphate salt-containing compositions disclosed herein. Water or oil-soluble or dispersible products can be obtained by such quaternization.
- In some aspects, the pharmaceutical compositions disclosed herein can include an effective amount of serine and/or one or more phosphate salts. The terms “effective amount” and “effective to treat,” as used herein, refer to an amount or a concentration of one or more compounds or a pharmaceutical composition described herein utilized for a period of time (including acute or chronic administration and periodic or continuous administration) that is effective within the context of its administration for causing an intended effect or physiological outcome (e.g., treatment or prevention of plaque or periodontal disease). In some aspects, pharmaceutical compositions can further include one or more additional compounds, drugs, or agents used for the treatment of plaque and/or periodontal disease in amounts effective for causing an intended effect or physiological outcome (e.g., treatment or prevention of plaque or periodontal disease).
- The pharmaceutical compositions disclosed herein can be formulated or adapted for administration to a subject via any oral route, e.g., any oral route approved by the Food and Drug Administration (FDA). Exemplary methods are described in the FDA Data Standards Manual (DSM) (available at http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/DataStandardsManualmonographs).
- For example, pharmaceutical compositions of this invention can be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets (e.g., confections such as (soft) chewable tablets), emulsions and aqueous suspensions, dispersions, pastes or powders (e.g., dentifrices or toothpastes), gums (e.g., chewing gums), and solutions (e.g., mouthwashes or other rinses). In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions or emulsions are administered orally, the active ingredient may be suspended or dissolved in an oily phase combined with emulsifying or suspending agents. If desired, certain sweetening, flavoring, or coloring agents can be added.
- In some aspects, an effective dose of a pharmaceutical composition of this invention can include, but is not limited to, e.g., about 0.00001, 0.0001, 0.001, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.25, 1.5, 1.75, 2, 2.5, or 3-10,000 mg/kg/day serine and/or one or more phosphate salts, or according to the requirements of the particular pharmaceutical composition.
- When the pharmaceutical compositions disclosed herein include a combination of a serine- and phosphate salt-containing composition described herein and one or more additional compounds (e.g., one or more additional compounds, drugs, or agents used for the treatment of plaque and/or periodontal disease), both the compound and the additional compound should be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen. The additional agents can be administered separately, as part of a multiple dose regimen, from the compounds of this invention. Alternatively, those agents can be part of a single dosage form, mixed together with the compounds of this invention in a single composition.
- In some aspects, the pharmaceutical compositions disclosed herein can be included in a container, pack, or dispenser together with instructions for administration.
- The methods disclosed herein contemplate administration of an effective amount of a compound or composition to achieve the desired or stated effect. Typically, the compounds or compositions of the invention will be administered from about 1 to about 6 times per day. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that can be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w). Alternatively, such preparations can contain from about 20% to about 80% active compound. In some aspects, the present disclosure provides methods for using a composition comprising serine and/or one or more phosphate salts, including pharmaceutical compositions (indicated below as ‘X’) disclosed herein in the following methods:
- Substance X for use as a medicament in the treatment of one or more diseases or conditions disclosed herein (e.g., plaque, referred to in the following examples as ‘Y’). Use of substance X for the manufacture of a medicament for the treatment of Y; and substance X for use in the treatment of Y.
- In some aspects, the methods disclosed include the administration of a therapeutically effective amount of one or more of the compounds or compositions described herein to a subject (e.g., a mammalian subject, e.g., a human subject) who is in need of, or who has been determined to be in need of, such treatment. In some aspects, the methods disclosed include selecting a subject and administering to the subject an effective amount of one or more of the compounds or compositions described herein, and optionally repeating administration as required for the prevention or treatment of plaque and/or periodontal disease.
- In some aspects, subject selection can include obtaining a sample from a subject (e.g., a candidate subject) and testing the sample for an indication that the subject is suitable for selection. In some aspects, the subject can be confirmed or identified, e.g. by a health care professional, as having had or having a condition or disease (e.g., periodontal disease). In some aspects, suitable subjects include, for example, subjects who have or had a condition or disease but that resolved the disease or an aspect thereof, present reduced symptoms of disease (e.g., relative to other subjects (e.g., the majority of subjects) with the same condition or disease), or that survive for extended periods of time with the condition or disease (e.g., relative to other subjects (e.g., the majority of subjects) with the same condition or disease), e.g., in an asymptomatic state (e.g., relative to other subjects (e.g., the majority of subjects) with the same condition or disease). In some aspects, exhibition of a positive immune response towards a condition or disease can be made from patient records, family history, or detecting an indication of a positive immune response. In some aspects, multiple parties can be included in subject selection. For example, a first party can obtain a sample from a candidate subject and a second party can test the sample. In some aspects, subjects can be selected or referred by a medical practitioner (e.g., a general practitioner). In some aspects, subject selection can include obtaining a sample from a selected subject and storing the sample or using the sample in the methods disclosed herein. Samples can include, e.g., plaque or saliva.
- In some aspects, methods of treatment can include a single administration, multiple administrations, and repeating administration of one or more compounds disclosed herein as required for the prevention or treatment of the disease or condition from which the subject is suffering (e.g., periodontal disease). In some aspects, methods of treatment can include assessing a level of disease in the subject prior to treatment, during treatment, or after treatment. In some aspects, treatment can continue until a decrease in the level of disease in the subject is detected.
- The term “subject,” as used herein, refers to any animal. In some instances, the subject is a mammal. In some instances, the term “subject,” as used herein, refers to a human (e.g., a man, a woman, or a child).
- The terms “administer,” “administering,” or “administration,” as used herein, refer to orally administering a compound or composition, regardless of form. For example, the methods disclosed herein include administration of an effective amount of a compound or composition to achieve the desired or stated effect. The pharmaceutical compositions disclosed herein can optionally be administered to the oral cavity or specific portions of the oral cavity (e.g., one or more teeth, or one or more portions of one or more teeth (e.g., exposed enamel, dentine, or cementum)) using one or more devices known in the art, e.g., brushes (e.g., toothbrushes), floss or flossers (e.g., dental floss), irrigators (e.g., oral irrigators), picks (e.g., dental picks or toothpicks), scrapers (e.g., tongue cleaners or scrapers), spatulas, sticks, retainers or mouth guards, etc.
- The terms “treat”, “treating,” or “treatment,” as used herein, refer to partially or completely alleviating, inhibiting, ameliorating, or relieving the disease or condition from which the subject is suffering. This means any manner in which one or more of the symptoms of a disease or disorder (e.g., plaque or periodontal disease) are ameliorated or otherwise beneficially altered. As used herein, amelioration of the symptoms of a particular disorder (e.g., plaque) refers to any lessening, whether permanent or temporary, lasting or transient that can be attributed to or associated with treatment by the compositions and methods of the present invention. In some embodiments, treatment can promote or result in, for example, a decrease in amount of plaque (e.g., in a subject) relative to the amount of plaque prior to treatment; or reductions in one or more symptoms associated with one or more periodontal diseases (e.g., gingivitis) in a subject relative to the subject's symptoms prior to treatment.
- The terms “prevent,” “preventing,” and “prevention,” as used herein, shall refer to a decrease in the occurrence of a disease or decrease in the risk of acquiring a disease or its associated symptoms in a subject. The prevention may be complete, e.g., the total absence of disease in a subject. The prevention may also be partial, such that the occurrence of the disease in a subject is less than, occurs later than, or develops more slowly than that which would have occurred without the present invention.
- Specific dosage and treatment regimens for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the disease, condition or symptoms, the patient's disposition to the disease, condition or symptoms, and the judgment of the treating physician.
- An effective amount can be administered in one or more administrations, applications or dosages. A therapeutically effective amount of a therapeutic compound (i.e., an effective dosage) depends on the therapeutic compounds selected. Moreover, treatment of a subject with a therapeutically effective amount of the compounds or compositions described herein can include a single treatment or a series of treatments. For example, effective amounts can be administered at least once. The compositions can be administered one from one or more times per day to one or more times per week; including once every other day. The skilled artisan will appreciate that certain factors can influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health or age of the subject, and other diseases present.
- Following administration, the subject can be evaluated to detect, assess, or determine their level of disease. In some instances, treatment can continue until a change (e.g., reduction) in the level of disease in the subject is detected. Upon improvement of a patient's condition (e.g., a change (e.g., decrease) in the level of disease in the subject), a maintenance dose of a compound, or composition disclosed herein can be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, can be reduced, e.g., as a function of the symptoms, to a level at which the improved condition is retained. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
- Twenty-one amino acids that comprise the bulk of the amino acids found in humans were tested for their potential effects on intra-oral pH. These amino acids included: glycine, alanine, glutamic acid, glutamine, aspartic acid, valine, histidine, leucine, isoleucine, cystine, cysteine, arginine, lysine, phenylalanine, serine, tyrosine, threonine, proline, methionine, tryptophan, and asparagine. Samples of each amino acid were obtained (Sigma-Aldrich, St. Louis, Mo.) for study of their acidic and alkalinic tendencies within the human oral cavity, as it relates to elements of periodontitis pathology (e.g., dental caries, dental calculus, and gingivitis).
- To obtain human salivary sediment for performance of the experiments described herein, paraffin wax (4.02 g) was chewed by human subjects (including some subjects 70+ years of age, where oral alkalinity is commonly more prevalent) to stimulate the flow of saliva. Prior to the experiment, the subjects fasted for 12 hours and abstained from oral hygiene for at least 24 hours (to enable spontaneous dental plaque bacterial growth and buildup on their teeth and other oral surfaces (Kleinberg. I., 1967, Arch. Oral Biol., 1457-1473)). As a result of this process, oral bacteria were dislodged by the inert paraffin wax from the teeth and oral soft tissue surfaces in the mouths of the human subjects. About 40 ml of whole saliva was then collected from each subject by expectoration into a 50 ml polypropylene centrifuge tube chilled by surrounding it with cracked ice (Korayem, M. R., Traudt, M., and Kleinberg, I., 1990; Sandham, H. J. and Kleinberg, I., 1973).
- The saliva collected was centrifuged at 1740 g in an International Equipment Company clinical centrifuge (Needham Heights, Mass.) for 15 min. at 4° C. The supernatant was decanted and discarded. To wash the remaining bacterial sediment, 40 ml of ice-cold distilled water was added and mixed in a vortex mixer. The resulting sediment-water mixture was centrifuged at 1740 g for 15 min. at 4° C. The supernatant was again decanted and discarded. This bacterial sediment washing procedure was repeated twice. To the washed bacterial sediment, 10 ml of deionized water was added and the composition was then mixed briefly and thoroughly in a vortex mixer. The sediment was transferred to a 15 ml polypropylene centrifuge tube. The resulting suspension was centrifuged at 1740 g for 15 min. at 4° C. and the resulting supernatant was aspirated and discarded.
- To the packed 1.0 ml of salivary sediment obtained after centrifugation, 1.0 ml of de-ionized water was added to make a 50% salivary sediment suspension for the preparation of the following standard incubation mixtures: salivary sediment at 16.7% (v/v), with and without added individual amino acids: serine, glycine, alanine, valine, and/or histidine, etc. at either a 90 or 120 mM concentration; and leucine, isoleucine, aspartic acid, glutamine, cysteine, cystine, lysine, arginine, tyrosine, phenylalanine, threonine, proline, methionine, tyrosine, glutamine, and/or asparagine, each at 9 mM. These mixtures were each prepared in the presence or absence of 28 mM urea, which has a relatively high pH.
- The initial pH of the incubation mixtures was carefully adjusted to or near 7.0 with either 1.0 M NaOH or 1.0 M HCl. Each bacterial mixture was then incubated overnight in a water bath at 37° C. The pH of each mixture was then determined using a combined pH and reference electrode (Radiometer Analytical SAS, Villeurbanne, France) at pre-determined time intervals.
- Separately, incubation mixtures containing salivary sediment at 16.7% (v/v) and 6.7 or 8.3 mM serine in the presence or absence of 6.7 mM urea, 20 or 25 mM serine and/or 3 mM sodium phytate (Sigma-Aldrich, St. Louis, Mo.), both in the presence or absence of 6.7 mM urea were prepared. Mixtures were incubated overnight at 37° C. in a water bath incubator (Kleinberg, I. and Hall, G., 1968; Salako, N. O. and Kleinberg, I., 1989), after adjusting the initial pH to or near 7.0 with 1N NaOH or 1N HCl.
- Separately, incubation mixtures containing salivary sediment at 16.7% (v/v), 20 or 25 mM serine, and 6 mM sodium phytate were prepared in the presence or absence of 6.7 mM urea. Mixtures were incubated overnight at 37° C. in a water bath incubator, after adjusting the initial pH to or near 7.0 with 1N NaOH or 1N HCl.
- Separately, incubation mixtures containing salivary sediment at 16.7% (v/v), 238 mM serine, and 6 mM sodium phytate were prepared in the presence or absence of 6.7 mM urea. Mixtures were incubated overnight at 37° C. in a water bath incubator, after adjusting the initial pH to or near 7.0 with 1N NaOH or 1N HCl.
- Separately, incubation mixtures were prepared containing a sample of human molar tooth (e.g., enamel crown with undesirable exposed dentin covered by and hence painted over with inert nail polish (
FIG. 23 )), along with salivary sediment at 16.7% (v/v), 238 mM serine, and 6.0 mM sodium phytate, optionally with one or more other amino acids at the concentrations recited above, in the presence or absence of 6.7 mM urea. Aliquots (200 μl) from each incubation mixture were withdrawn at 0, 1, 2, 4, and 21 hours of incubation and centrifuged at 10,000 g for 10 min. at 4° C. Supernatants were stored at −20° C. for subsequent analysis of calcium by atomic absorption spectroscopy 3110 (PerkinElmer, Norwalk, Conn.). - Similar incubation mixtures were also prepared containing a sample of tooth cementum (e.g., from the roots of human molar teeth (
FIG. 24 )). The tooth coronal surfaces were partially covered with inert nail polish (Sally Hanson, Del Laboratory Inc., Garden City, N.Y.), and then prepared and incubated in similar fashion described above for the mixtures containing a sample of human molar tooth. Aliquots (200 μl) from each incubation mixture were withdrawn at 0, 1, 2, 4, and 21 hours of incubation and centrifuged at 10,000 g for 10 min. at 4° C. Supernatants were stored at −20° C. for subsequent analysis of calcium by atomic absorption spectroscopy 3110 (PerkinElmer, Norwalk, Conn.). - Separately, incubation mixtures containing salivary sediment at 16.7% (v/v), 238 mM serine, and 6 mM sodium phytate, with or without 6.7 mM urea, were prepared and incubated without adjusting the initial pH to or near 7.0, except for salivary sediment mixed with de-ionized water, which was adjusted to pH 8.10 with 1 M NaOH. Determination of the pH of each of these experimental entities were carried out at pre-determined time intervals (i.e., at 0 min., 15 min., 30 min., 1 h, 2 h, 3 h, 4 h, and 21 h) with a pH meter (Radiometer Copenhagen, type PHM26, Radiometer America, Westlake, Ohio) and a combination pH electrode (Radiometer Analytical, Cedex, France).
- It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
-
- 1. Biswas, S. D. and Kleinberg, I. 1971. Effect of urea concentration on its utilization, on the pH and the formation of ammonia and carbon dioxide in the human salivary sediment system. Arch. Oral Biol. 16: 759-780.
- 2. Denepitiya L. and Kleinberg I. 1982. A comparison of the microbial composition of pooled human dental plaque and salivary sediment. Arch. Oral Biol. 27: 739-745.
- 3. Golub, L. M., Borden, S. M., and Kleinberg, I. 1971. Urea content of gingival crevicular fluid and its relation to periodontal disease in humans. J. Periodont. Res. 6: 243-251.
- 4. Grases, F., Perelló, J., Sanchis, P., Isern, B., Prieto, R. M., Costa-Bauzá, A., Santiago, C., Ferragut, M. L., and Frontera, G. 2009. Anticalculus effect of a triclosan mouthwash containing phytate: a double-blind, randomized, three-period cross over trial. J. Periodont. Res. 44: 616-621.
- 5. Grenby, T. H. 1967. Phytates in decalcification tests in vitro. Arch. Oral Biol. 12: 531-537.
- 6. Heaney, R. P., Weaver, C. M., and Fitzsimmons, M. L. 1991. Soybean phytate content: effect on calcium absorption. Am. J. Clin. Nutr. 53: 745-747.
- 7. Kaufman, W. and Kleinberg, I. 1971. Effect of pH on calcium binding by phytic acid and its inositol phosphoric acid derivatives and on the solubility of their calcium salts. Arch. Oral Biol. 16: 445-460.
- 8. Kleinberg, I. 1967. Effect of urea concentration on human plaque pH levels in situ. Arch. Oral. Biol. 12: 1475-1484.
- 9. Kleinberg. I. 1967. Effect of varying sediment and glucose concentrations of the pH and acid production in human salivary sediment mixtures. Arch. Oral. Biol. 12: 1457-1473.
- 10. Kleinberg, I. and Hall, G. 1968. pH and depth of gingival crevices in different areas of the mouths of fasting humans. J. Periodont. Res. 3: 109-117.
- 11. Kleinberg, I., Craw, D., and Komiyma, K., 1973. Effect of salivary supernatant on the glycolytic activity of the bacteria in salivary sediment. Arch. Oral Biol. 18: 787-798.
- 12. Kleinberg, I., Kanapka, J. A., and Craw, D. 1977. The effect of saliva and salivary factors on the metabolism of the mixed oral flora, in Microbial Aspects of Dental Caries. Stiles, H. M., Loesche, W. J. and O'Brien, T. C., Eds. Information Retrieval Inc., Washington, D.C., 433.
- 13. Kleinberg, I., Kanapka, J. A., Chatterjee, R., Craw, D., D'Angelo, N., and Sandham, H. J. 1979. Metabolism of nitrogen by the oral mixed bacteria, in Saliva and Dental Caries. Kleinberg, I., Ellison, S. A., and Mandel, I. D., Eds. Information Retrieval, Inc., New York, N.Y., 357.
- 14. Korayem, M. R., Traudt, M., and Kleinberg, I. 1990. Oxygen uptake and its relation to pH in a human salivary system during fermentation of glucose. Arch. Oral Biol. 35: 759-764.
- 15. Jacobson, M. and Kesel, R. G. 1950. Salivary ammonia and its correlation to dental calculus. J. Dent. Res. 29: 364-374.
- 16. Takhashi, N. 2005. Microbial ecosystem in the oral cavity: Metabolic diversity in an ecological niche and its relationship with oral diseases. Int. Congr. Ser. 1284: 103-112.
- 17. Onosi, M., Tachibana, Y., Nakamura, T., Takakuwa, S., and Ishioka, K. 1957. Preferential sites of the urea hydrolyzing organisms in the mouth. Tokyo Med. Dent. Bull. 4, 253-257.
- 18. Salako, N. O. and Kleinberg, I. 1989. Incidence of selected ureolytic bacteria in human dental plaque from sites with differing salivary access. Arch. Oral Biol. 34: 787-791.
- 19. Sandham, H. J. and Kleinberg, I. 1973. Effect of fluoride on carbon dioxide and acid formation in salivary sediment mixtures incubated with glucose. Arch. Oral Biol. 18: 211-225.
- 20. Singer, D. L. and Kleinberg, I. 1978. Ammonia and urea content of human incisor plaques. Arch Oral Biol. 23: 1983-1987.
- 21. Jin, Y. and Yip, H.-K. 2002. Supragingival calculus: Formation and Control. Crit. Rev. Oral Biol. Med. 13: 426-441.
Claims (18)
1. A method of treating or preventing periodontitis and dental calculus accumulation, the method comprising administering to the oral environment of a subject, an effective amount of an oral composition comprising serine and at least one organic mono-phosphate or multi-phosphate salt.
2. The method of claim 1 , wherein the composition further includes a buffer providing the composition with a pH of between about 6.1 and 7.0.
3. The method of claim 2 , wherein the composition is provided as an orally acceptable dosage form, wherein the introduction of the composition to a subject suffering from periodontitis or dental calculus accumulation, reduces the alkalinity and thereby increases calcium concentration in the saliva by dissolving the calculus.
4. The method of claim 2 , wherein the pH of the composition is between about 6.1 and about 6.3.
5. The method of claim 2 , wherein the pH of the composition is between about 6.7 and about 7.0.
6. The method of claim 1 , wherein the organic mono-phosphate or multi-phosphate salt is a biological salt.
7. The method of claim 6 , wherein the biological salt is an inositol.
8. The method of claim 7 , wherein the inositol is a phytate.
9. The method of claim 8 , wherein the phytate is sodium phytate.
10. The method of claim 3 , wherein the orally acceptable dosage form is selected from the group consisting of capsules, tablets, emulsions, aqueous suspensions, dispersions, pastes, powders, gums, and solutions.
11. The method of claim 10 , wherein the orally acceptable dosage form comprises one or more carriers, one or more lubricating agents, or one or more diluents.
12. The method of claim 11 , wherein the carrier is lactose or corn starch, the lubricating agent is magnesium stearate, and the diluent is lactose or dried corn starch.
13. The method of claim 2 , wherein the orally acceptable dosage form comprises one or more sweetening, flavoring, or coloring agents.
14. The method of claim 1 wherein the subject is at risk of developing plaque or periodontal disease.
15. The method of claim 14 , wherein the subject is a human.
16. The method of claim 15 , wherein the periodontal disease is gingivitis.
17. The method of any of claim 1 , wherein the oral composition is applied to one or more teeth of the subject.
18. The method of claim 17 , wherein the oral composition is applied to the enamel, exposed dentine, or cementum of one or more teeth of the subject.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/014,834 US20180296454A1 (en) | 2016-05-05 | 2018-06-21 | Compositions for treating periodontitis and dental calculus accumulation |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662332201P | 2016-05-05 | 2016-05-05 | |
US15/587,265 US10076481B2 (en) | 2016-05-05 | 2017-05-04 | Compositions for treating periodontitis and dental calculus accumulation |
US16/014,834 US20180296454A1 (en) | 2016-05-05 | 2018-06-21 | Compositions for treating periodontitis and dental calculus accumulation |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/587,265 Continuation US10076481B2 (en) | 2016-05-05 | 2017-05-04 | Compositions for treating periodontitis and dental calculus accumulation |
Publications (1)
Publication Number | Publication Date |
---|---|
US20180296454A1 true US20180296454A1 (en) | 2018-10-18 |
Family
ID=60203217
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/587,265 Active US10076481B2 (en) | 2016-05-05 | 2017-05-04 | Compositions for treating periodontitis and dental calculus accumulation |
US16/014,834 Abandoned US20180296454A1 (en) | 2016-05-05 | 2018-06-21 | Compositions for treating periodontitis and dental calculus accumulation |
US18/413,453 Pending US20240300675A1 (en) | 2016-05-05 | 2024-01-16 | Solar Sail for Orbital Maneuvers |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/587,265 Active US10076481B2 (en) | 2016-05-05 | 2017-05-04 | Compositions for treating periodontitis and dental calculus accumulation |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/413,453 Pending US20240300675A1 (en) | 2016-05-05 | 2024-01-16 | Solar Sail for Orbital Maneuvers |
Country Status (2)
Country | Link |
---|---|
US (3) | US10076481B2 (en) |
WO (1) | WO2017192200A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110478265A (en) * | 2019-07-29 | 2019-11-22 | 靖江市盛金科技有限公司 | A kind of bioactive substance phytic acid ammonia sodium and its application in oral care product |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018445164A1 (en) | 2018-10-11 | 2021-04-22 | Sanifit Therapeutics S.A. | Inositol phosphates for the treatment of ectopic calcification |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5624906A (en) * | 1994-12-08 | 1997-04-29 | Lever Brothers Company, Division Of Conopco, Inc. | Oral hygiene compositions comprising heteroatom containing alkyl aldonamide compounds |
US20040022392A1 (en) * | 2002-05-03 | 2004-02-05 | Griesinger David H. | Sound detection and localization system |
US20150094836A1 (en) * | 2012-04-26 | 2015-04-02 | Taktia Llc | Systems and methods for performing a task on a material, or locating the position of a device relative to the surface of the material |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4376762A (en) * | 1981-09-30 | 1983-03-15 | Colgate-Palmolive Company | Functional agglomerated speckles, dentifrices containing such speckles and methods for manufacturing such speckles and dentifrices containing them |
FR2679515B1 (en) * | 1991-07-26 | 1996-01-26 | Onera (Off Nat Aerospatiale) | SOLAR SAILS. |
WO1996005803A1 (en) | 1994-08-22 | 1996-02-29 | Quest International B.V. | Breath malodour reduction |
US6734155B1 (en) * | 1997-07-09 | 2004-05-11 | The Procter & Gamble Company | Cleaning compositions comprising an oxidoreductase |
DE19825785C2 (en) * | 1998-06-10 | 2000-04-27 | Deutsch Zentr Luft & Raumfahrt | Solar sailer with sail film and folding tubes |
GB0016067D0 (en) * | 2000-06-30 | 2000-08-23 | Procter & Gamble | Oral compositions |
DE10109529B4 (en) * | 2001-02-28 | 2005-10-27 | Deutsches Zentrum für Luft- und Raumfahrt e.V. | Device with a flat compressed in cross-section and rolled up length mast |
JP3541225B2 (en) * | 2001-07-16 | 2004-07-07 | 宇宙科学研究所長 | Large membrane space structure and deployment method thereof |
US7982008B2 (en) | 2002-11-27 | 2011-07-19 | David Bar-Or | Treatment of diseases and conditions mediated by increased phosphorylation |
US20040223921A1 (en) * | 2003-05-07 | 2004-11-11 | Rau Allen H. | Oral care tablet |
US20070116800A1 (en) * | 2005-11-23 | 2007-05-24 | The Coca-Cola Company | Chewing Gum with High-Potency Sweetener |
BRPI0620220A2 (en) * | 2005-12-20 | 2011-11-01 | Procter & Gamble | oral care compositions comprising zinc and phytate |
JP2007254315A (en) | 2006-03-22 | 2007-10-04 | Koki Kobayashi | Rock salt-containing sanitary composition for oral cavity |
JP5653998B2 (en) | 2009-04-01 | 2015-01-14 | コルゲート・パーモリブ・カンパニーColgate−Palmolive Company | Metabolites for oral health and their use |
BR112012008680A2 (en) | 2009-10-26 | 2016-04-19 | Colgate Palmolive Co | oral care composition and method for treating or preventing bad oral odor |
WO2011109119A1 (en) | 2010-01-08 | 2011-09-09 | President And Fellows Of Harvard College | Methods and coatings for treating biofilms |
WO2011123123A1 (en) | 2010-03-31 | 2011-10-06 | Colgate-Palmolive Company | Oral care composition |
WO2012151554A1 (en) | 2011-05-04 | 2012-11-08 | President And Fellows Of Harvard College | Polyamines for treating biofilms |
US20140314691A1 (en) * | 2013-03-14 | 2014-10-23 | C3 Jian, Inc. | Compositions for improving the appearance and/or health of teeth |
CN109908017A (en) | 2013-12-19 | 2019-06-21 | 高露洁-棕榄公司 | Oral care composition |
-
2017
- 2017-02-24 WO PCT/US2017/019458 patent/WO2017192200A1/en active Application Filing
- 2017-05-04 US US15/587,265 patent/US10076481B2/en active Active
-
2018
- 2018-06-21 US US16/014,834 patent/US20180296454A1/en not_active Abandoned
-
2024
- 2024-01-16 US US18/413,453 patent/US20240300675A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5624906A (en) * | 1994-12-08 | 1997-04-29 | Lever Brothers Company, Division Of Conopco, Inc. | Oral hygiene compositions comprising heteroatom containing alkyl aldonamide compounds |
US20040022392A1 (en) * | 2002-05-03 | 2004-02-05 | Griesinger David H. | Sound detection and localization system |
US20150094836A1 (en) * | 2012-04-26 | 2015-04-02 | Taktia Llc | Systems and methods for performing a task on a material, or locating the position of a device relative to the surface of the material |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110478265A (en) * | 2019-07-29 | 2019-11-22 | 靖江市盛金科技有限公司 | A kind of bioactive substance phytic acid ammonia sodium and its application in oral care product |
Also Published As
Publication number | Publication date |
---|---|
US20170319452A1 (en) | 2017-11-09 |
US10076481B2 (en) | 2018-09-18 |
WO2017192200A1 (en) | 2017-11-09 |
US20240300675A1 (en) | 2024-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Salisbury | Antimicrobial strategies in the prevention of dental caries | |
RU2441641C1 (en) | Compositions and means of cleaning | |
JP6784491B2 (en) | Oral composition for preventing plaque formation | |
JPH06505745A (en) | Non-antibacterial tetracycline composition with anti-plaque properties | |
TW201106954A (en) | Oral compositions containing polyguanidinium compounds and methods of manufacture and use thereof | |
US10391038B2 (en) | Tooth sealant | |
KR101354923B1 (en) | Oral hygiene composition using an extract of curcuma longa and an extract eriobotrya japonica | |
TW201440802A (en) | Oral care composition containing ionic liquids | |
US20180296454A1 (en) | Compositions for treating periodontitis and dental calculus accumulation | |
JP2011153138A (en) | Composition for oral cavity | |
Sahin et al. | Antibacterial efficacy and remineralization capacity of glycyrrhizic acid added casein phosphopeptide‐amorphous calcium phosphate | |
US20040241107A1 (en) | Toothpaste containing anticancer agents | |
Porciani et al. | Whitening effect by stain inhibition from a chewing gum with sodium hexametaphosphate in a controlled twelve-week single-blind trial | |
WO2022145325A1 (en) | Composition for oral cavity | |
JP2022103980A (en) | Composition for oral cavity | |
JP6030069B2 (en) | Oral cleaning composition for prevention and / or treatment of periodontal disease | |
US20060246016A1 (en) | Toothpaste containing anticancer agents | |
CN108078822B (en) | Special white and black toothpaste | |
CA2482230A1 (en) | Polyphosphonate derivatives for toothpaste compositions | |
EP4364719A1 (en) | Oral pharmaceutical composition for preventing and/or treating diseases of the soft and hard tissues surrounding the tooth in the oral cavity | |
US20040028623A1 (en) | Formulations for the removal of dental plaque, tartar and dental stains | |
JP2018127427A (en) | Saliva secretion promoter, food composition containing the same, and oral composition | |
WO2023175655A1 (en) | Agent for oral diseases | |
JP2866393B2 (en) | Oral composition for inhibiting plaque accumulation | |
WO2006110183A2 (en) | Dental formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY O Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KLEINBERG, ISRAEL;CHATTERJEE, ROBI;REEL/FRAME:046224/0071 Effective date: 20170509 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |